Professor Lorraine O'Driscoll

Professor of Pharmacology & Biomedicine, Pharmacy

Biography

Lorraine O'Driscoll (BSc(Hons, Pharm), MSc(Res, Clin Pharm), MA(Ed), PhD(Biotech), FTCD, FRSB, MRIA) Lorraine holds a BSc(Hons), pharmacology; MSc(Res), clinical pharmacology; MA, education; PhD, biotechnology. In 2012, she was elected to Fellowship in TCD. Following her PhD, Lorraine undertook biotechnology/biomedical research for US and EU industry (including Berlex; Archport Ltd-Axonobel; MediSyn Ltd; MedaNova Ltd.) before returning to academic research & teaching. At post-doctoral level, she gained experience at the Dana-Farber Harvard Cancer Institute and University of Miami. Prior to joining TCD in 2008, Lorraine most recently held the position of Senior Research Programme Leader and Lecturer in School of Biotechnology, DCU. Her research group focuses on diagnostic, prognostic and predictive biomarkers; discovering new therapeutic targets; cancer cells communication via exosomes, microvesicles and CTCs; elucidating and circumventing resistance to targets agents and classical chemotherapy; associations between obesity, metabolic syndrome and cancer. She has been a P.I. on 5 cancer clinical trials with ICORG. She is TCD's Principal Investigator on SFI-supported Molecular Therapeutics for Cancer Ireland; Strand Leader of Irish Cancer Society-supported Breast-PREDICT; and P.I. and Chair, H2020-supported European Network Cooperation in Science and Technology focussed on Exosomes & Microvesicles in Health & Disease which brings together researchers from 27 European countries, 3 US universities, Australia and 7 industry partners. In 2017, she was awarded approx. 4,000,000 as Director of a H2020 ITN aimed at training 15 PhD students in TRAIN-EV i.e. training in extracellular vesicles: for benefit in health and disease. She has developed tailored courses for academia (e.g. FEBS), semi-state bodies (e.g. IDA) and industry. Her graduates and mentees are now employed at NIH; Pfizer; Amgen; Leo; Roche; AstraZeneca; ICON plc; 2 are entrepreneurs/company CEOs; 2 are Managers of Research Centres; others hold lecturing and research posts in academia.

Publications and Further Research Outputs

Peer-Reviewed Publications
Non-Peer-Reviewed Publications

O'Neill S, O'Driscoll L, Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. , Obes. Rev., 16, (1), 2015, p1 - 12Journal Article, 2015, DOI , URL , TARA - Full Text
Martinez VG, O'Driscoll L, Neuromedin U: A Multifunctional Neuropeptide with Pleiotropic Roles., Clin. Chem., 61, (3), 2015, p471 - 482Journal Article, 2015, DOI , URL , TARA - Full Text
Bohl M, Bjørnshave A, Rasmussen KV, Grethe Schioldan A, Amer B, Larsen MK, Dalsgaard TK, Holst JJ, Herrmann A, O'Neill S, O'Driscoll L, Afman L, Jensen E, Christensen MM, Gregersen S, Hermansen K. , Dairy proteins, dairy lipids, and postprandial lipemia in persons with abdominal obesity (DairyHealth): a 12-wk, randomized, parallel-controlled, double-blinded, diet intervention study. , Amer. J. Clin. Nutrition. , 101, (4), 2015, p870 - 878Journal Article, 2015, DOI , URL , TARA - Full Text
Breen L, O'Driscoll L, Clynes M. , Gene Expression Microarray Technology: Some Applications in Lung Cancer Research., Cancer Genomics Proteomics, 3, (3-4), 2006, p197 - 202Journal Article, 2006, TARA - Full Text
O'Driscoll L, Kenny E, Perez de Villarreal M, Clynes M, Detection of Specific mRNAs in Culture Medium Conditioned by Human Tumour Cells: Potential for New Class of Cancer Biomarkers in Serum. , Cancer Genomics & Proteomics , 2, (1), 2005, p43 - 52Journal Article, 2005, URL , TARA - Full Text
Clynes M, Heenan M, McBride S, Cleary I, O'Driscoll L, Moran E. , Multiple drug resistance in variants of a human lung cell line exposed to adriamycin and VP-16. , J. Exp. & Clin. Cancer Res. , 14, 1995, p15 - 18Journal Article, 1995, TARA - Full Text
Corcoran C, Rani S, Prencipe M, O'Neill A, Watson W, O'Driscoll L. , miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. , J. Extracellular Vesicles. , 3, (24214), 2014, pp360 - 360Published Abstract, 2014, DOI , URL , TARA - Full Text
O'Brien K, Corcoran C, Rani S, Crown J, Radomski M, O'Driscoll L., miR-134 transported in extracellular vesicles reduces triple-negative breast cancer aggression., J. Extracell. Vesicles., 3, (24214), 2014, pp143 - 144Published Abstract, 2014, DOI , URL , TARA - Full Text
Corcoran C, Rani S, Breslin S, Ghobrial IM, Crown J, O'Driscoll L., The potential of miR-630, an IGF1R regulator, as a predictive biomarker for HER2-targeted drugs. , J. Clin. Oncol., 31, (15), 2013, pp620 - 621Published Abstract, 2013, URL , TARA - Full Text
Breslin S, Corcoran C, Rani S, Crown J, O'Driscoll L. , Assessment of neratinib-resistance and cross-resistance in HER2-overexpressing breast cancer cells. , J. Clin. Oncol. , 31, (15), 2013, pp11520 - 11521Published Abstract, 2013, URL , TARA - Full Text
O'Brien K, Corcoran C, Rani S, McDonnell S, Hughes L, Radomski M, Crown J, O'Driscoll L. , The Relevance of exosomal-miRNAs in triple-negative breast cancer progression. , J. Extracell. Vesicles., 2, 2013, pp122 - 122Published Abstract, 2013, DOI , URL , TARA - Full Text
Corcoran C, Rani S, O'Neill A, Prencipe M, O'Brien A, O'Brien K, Crown J, Watson WG, O'Driscoll L. , The relevance of exosomes in prostate cancer and their potential to confer docetaxel resistance to secondary cells. , Cancer Research , 72, (8), 2012, pp794 - 795Published Abstract, 2012, DOI , URL , TARA - Full Text
Eustace AJ, Browne BC, McDermott M, O'Leary P, O'Driscoll L, O'Brien N, Gallagher N, Watson W, Crown J, O'Donovan N. , Alterations in Apoptosis-related Genes in Cell Line Models of Acquired Lapatinib Resistance, Identifies Potential Therapeutic Targets for the Treatment of Lapatinib Resistant HER2-positive, Eur. J. Cancer, 48, 2012, pp44 - 45Published Abstract, 2012, DOI , URL , TARA - Full Text
Breslin S, Rani S, Corcoran C, O'Brien K, O'Driscoll L. , Generation and Characterisation of Neratinib-resistant Breast Cancer Cell Line Variants., Eur. J. Cancer, 48, 2012, pp32 - 33Published Abstract, 2012, DOI , URL , TARA - Full Text
Rani S, Germano S, Madden SF, Corcoran C, Breslin S, O'Brien NA, McDermott M, Browne B, O'Donovan N, Crown J, O'Driscoll L. , Neuromedin U: A potential predictive biomarker for HER2-targeted drugs. , J. Clin. Oncol. , 30, (15), 2012, pp617 - 617Published Abstract, 2012, DOI , URL , TARA - Full Text
O'Brien K, Rani S, Wallace R, McDonnell S, Hughes L, Radomski M and O'Driscoll L. , Can exosomes influence triple negative breast cancer metastasis?, J. Extracell. Vesicles., 51, 2012, pp74 - 75Published Abstract, 2012, DOI , URL , TARA - Full Text
Eustace AJ, Browne B, Madden SF, O'Driscoll L, McDermott M, O'Brien NA, Watson W, Crown J, Walsh N, O'Donovan N. , Effect of acquired resistance to lapatinib in HER2-positive breast cancer cells on the Bcl-2 family members MCL-1 and BAX. , J. Clin. Oncol. , Amer. Soc. Clin. Oncol. (ASCO), Chicago, US, June 2012, 30, (15), 2012, pp633 - 634Published Abstract, 2012, URL , TARA - Full Text
Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Crown J, Watson W, O'Driscoll L. , Exosomes: potential regulators and biomarkers of prostate cancer progression. , J. Extracell. Vesicles., 51, (76), 2012, pp34 - 35Published Abstract, 2012, DOI , URL , TARA - Full Text
Rani S, O'Brien K, McDonnell S, Hughes L, Friel AM, Radomski MW, Crown J, O'Driscoll L. , Triple-negative Breast Cancer Cells May Transfer Phenotypic Characteristics via Exosomes. , Eur. J Cancer , Europ. Soc. Med. Oncol., Stockholm, Sweden, Sept 2011, 47, 2011, pp143 - 144Published Abstract, 2011, DOI , URL , TARA - Full Text
Eustace AJ, Kennedy S, Larkin A, Mahgoub T, Tryfonopoulos D, O'Driscoll L, Clynes M, Crown J, O'Donovan N. , Identification of predictive biomarkers for dasatinib treatment of metastatic melanoma. , J. Clin. Oncol., Amer. Soc. Clin. Oncol., Chicago, US, 2011, 29, (15), 2011, pp8578 - 8578Published Abstract, 2011, URL , TARA - Full Text
O'Driscoll L. , microRNAs-key contributors to endocrinology. , BioScientifica, 25, (4), 2011, pp1-Published Abstract, 2011, URL , TARA - Full Text
Corcoran C, Rani S, O'Brien K, Crown J, O'Driscoll L. , Establishing and characterising new in vitro models of docetaxel-resistance in prostate cancer. , Eur. J. Cancer, Europ. Soc. Med. Oncol., Stockholm, Sweden, Sept 2011, 47, 2011, pp489 - 490Published Abstract, 2011, DOI , URL
Rani S, O'Driscoll L. , Function of beta cell and extracellular RNAs as potential biomarker. Defining beta cell function and elucidating extracellular RNAs as potential biomarker. , Academic Press, 2011Book, 2011
Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borràs FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Colás E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Krämer-Albers EM, Laitinen S, Lässer C, Lener T, Ligeti E, Linē A, Lipps G, Llorente A, Lötvall J, Manček-Keber M, Marcilla A, Mittelbrunn M, Nazarenko I, Nolte-'t Hoen EN, Nyman TA, O'Driscoll L, Olivan M, Oliveira C, Pállinger É, Del Portillo HA, Reventós J, Rigau M, Rohde E, Sammar M, Sánchez-Madrid F, Santarém N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MH, De Wever O, Biological properties of extracellular vesicles and their physiological functions., J. Extracellular Vesicles, 4, 2015, p27066 - 27098Journal Article, 2015, DOI , URL , TARA - Full Text
O'Driscoll L., Expanding on Exosomes and Ectosomes in Cancer, New Eng. J. Medicine, 372, (24), 2015, p2359 - 2362Journal Article, 2015, DOI , URL , TARA - Full Text
Lowry MC, Gallagher WM, O'Driscoll L, The Role of Exosomes in Breast Cancer, Clin. Chem., 61, (12), 2015, p1457 - 1465Journal Article, 2015, DOI , URL , TARA - Full Text
O'Brien K, Lowry MC, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RA, O'Driscoll L., miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity., Oncotarget, 6, (32), 2015, p32774 - 32789Journal Article, 2015, DOI , URL , TARA - Full Text
Lener T, Gimona M, Aigner L, Börger V, Buzas E, Camussi G, Chaput N, Chatterjee D, Court FA, Del Portillo HA, O'Driscoll L, Fais S, Falcon-Perez JM, Felderhoff-Mueser U, Fraile L, Gho YS, Görgens A, Gupta RC, Hendrix A, Hermann DM, Hill AF, Hochberg F, Horn PA, de Kleijn D, Kordelas L, Kramer BW, Krämer-Albers EM, Laner-Plamberger S, Laitinen S, Leonardi T, Lorenowicz MJ, Lim SK, Lötvall J, Maguire CA, Marcilla A, Nazarenko I, Ochiya T, Patel T, Pedersen S, Pocsfalvi G, Pluchino S, Quesenberry P, Reischl IG, Rivera FJ, Sanzenbacher R, Schallmoser K, Slaper-Cortenbach I, Strunk D, Tonn T, Vader P, van Balkom BW, Wauben M, Andaloussi SE, Théry C, Rohde E, Giebel B. , Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper., Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. , 30087, (4), 2015, p1 - 35Journal Article, 2015, DOI , URL , TARA - Full Text
Fais S, O'Driscoll L, Borras FE, Buzas E, Camussi G, Cappello F, Carvalho J, Cordeiro da Silva A, Del Portillo H, El Andaloussi S, Ficko Trček T Furlan R, Hendrix A, Gursel I, Kralj-Iglic V, Kaeffer B, Kosanovic M, Lekka ME, Lipps G, Logozzi M, A, Sammar M, Llorente A, Nazarenko I, Oliveira C, Pocsfalvi G, Rajendran L, Raposo G, Rohde E, Siljander P, van Niel G, Vasconcelos MH, Yáñez-Mó M, Yliperttula ML, Zarovni N, Bedina Zavec A, Giebel B., Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine, ASC Nano, 10, (4), 2016, p3886 - 3899Journal Article, 2016, DOI , URL
O'Neill S, Bohl M, Gregersen S, Hermansen K, O'Driscoll L., Blood-based biomarkers for metabolic syndrome, Trends in Endocrinology & Metabolism, 27, (6), 2016, p363 - 374Journal Article, 2016, DOI , URL , TARA - Full Text
Breslin S, O'Driscoll L, The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance., Oncotarget, 7, (29), 2016, p45745 - 45756Journal Article, 2016, DOI , URL , TARA - Full Text
Breslin S, O'Driscoll L., Three-dimensional cell culture: The missing link in drug discovery, Drug Discovery Today, 18, (5-6), 2013, p240 - 249Journal Article, 2013, DOI , URL , TARA - Full Text
Martinez VG, Rani S, Corcoran C, Crown J, O'Driscoll L., Neuromedin U to increase IL-6 levels and to expand cancer stem cells in HER2-positive breast cancer cells., J Clin. Oncol., 33, (15), 2015, pp614 - 615Published Abstract, 2015, URL , TARA - Full Text
Gene Expression Profiling, L O'Driscoll, 2nd Edition, New York:, Humana Press, 2009, 1 - 211Critical Edition (Book), 2009, TARA - Full Text
MicroRNA Profiling of Exosomes in, editor(s)Rani S , Methods in Molecular Biology, New York, Springer, 2017, pp37 - 46, [Daly M, O'Driscoll L]Book Chapter, 2017, DOI , URL , TARA - Full Text
Profiling Circulating miRNAs from the Plasma of Individuals with Metabolic Syndrome in, editor(s)Rani S , Meth. Mol. Biol., New York, Springer, 2017, pp141 - 149, [O'Neill S, O'Driscoll L]Book Chapter, 2017, DOI , URL , TARA - Full Text
Friel, A.M., Crown, J., O'Driscoll, L., Analysis of gene expression as relevant to cancer cells and circulating tumour cells, Methods in Molecular Biology, 784, 2011, p55-75Journal Article, 2011, DOI , URL
O'Driscoll, L., Editorial: Preface: Gene expression profiling methods and protocols second edition, Methods in Molecular Biology, 784, 2011Journal Article, 2011
O'Driscoll, L., O'Connor, R., Clynes, M., Anticancer Research: Preface, Anticancer Research, 27, (3 A), 2007Journal Article, 2007
O'Driscoll, L., O'Connor, R., Clynes, M., "Biotechnology, cancer and drug resistance: New targets, new diagnosis and new treatment for tumours resistant to current therapies". Preface, Anticancer Research, 24, (2 A), 2004Journal Article, 2004
O'Driscoll LR, Finlay GA, Fitzgerald MX, O'Connor CM., Matrixmetalloproteinases expression by alveolar macrophages in emphysema, Thorax, 51, (3), 1996, p1 - 2Journal Article, 1996, URL
O'Driscoll L, Stoorvogel W, Thery C, Buzas E, Nazarenko I, Siljander P, Yanez-Mo M, Fais S, Giebel B, Yliperttula M, European Network on Microvesicles and Exosomes in Health and Disease, European Journal of Pharmaceutical Sciences, 98, 2017, p1 - 3Journal Article, 2017, DOI , URL
Breslin S, Lowry M, O'Driscoll L, Neratinib-resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4, British Journal of Cancer, 116, (5), 2017, p620 - 625Journal Article, 2017, DOI , URL , TARA - Full Text
EV-TRACK Consortium,.. O'Driscoll L. , EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research., Nature Methods, 14, (3), 2017, p228 - 232Journal Article, 2017, DOI , URL
O'Driscoll L, Mechanisms of drug sensitivity and resistance in cancer., Curr. Cancer Drug Targets, 9, (3), 2009, p250 - 251Journal Article, 2009
O'Driscoll L, Doolan P, Clynes, M, 'Diagnostic, prognostic and/or predictive indicators of breast cancer', Publ.of the Int.Appl. without Int.search REP. - World Intellectual Property Organization, WO 2008132167 A3, 2009, 18 May 2009Patent, 2009
Martinez VG, Crown J, Porter RK, O'Driscoll L., Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer, International Journal of Cancer, 140, (12), 2017, p2771 - 2784Journal Article, 2017, DOI , URL , TARA - Full Text
Lowry MC, Gallagher WM, O'Driscoll L., The role of exosomes in breast cancer., Clinical Chemistry, 61, (12), 2015, p1457 - 1465Journal Article, 2015, DOI , URL , TARA - Full Text
Martinez VG, O'Neill S, Salimu J, Breslin S, Clayton A, Crown J, O'Driscoll L., Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles., Oncoimmunology, 6, (12), 2017, p530 - 540Journal Article, 2017, DOI , URL , TARA - Full Text
O'Neill S, Larsen MB, Gregersen S, Hermansen K, O'Driscoll L., miR-758-3p: a blood-based biomarker that's influence on the expression of CERP/ABCA1 may contribute to the progression of obesity to metabolic syndrome., Oncotarget, 9, (10), 2018, p9379 - 9390Journal Article, 2018, DOI , URL , TARA - Full Text
Lowry MC, O'Driscoll L, Can hi-jacking hypoxia inhibit extracellular vesicles in cancer?, Drug Discovery Today, 23, (6), 2018, p1267 - 1273Journal Article, 2018, DOI , URL
McNamee N, O'Driscoll L, Extracellular vesicles and anti-cancer drug resistance, BBA Cancer, 1870, (2), 2018, p123 - 136Journal Article, 2018, DOI , URL , TARA - Full Text
O'Driscoll L., Gene Expression Profiling: Methods and Protocols, Second Edition, Second, 2011, 1 - 211ppBook, 2011, URL
Thery C,...O'Driscoll L.. (alphabetical order).., Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines, J. Extracell. Vesicles, 2019, p1--Journal Article, 2019, DOI , URL , TARA - Full Text
Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J., Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL., BMC Cancer, 18, (1), 2018Journal Article, 2018, DOI , URL , TARA - Full Text
Gaynor N, Guibourdenche M, Browne B, O'Driscoll L, O'Brien N, O'Donovan N, Crown J, Collins D., Alterations to trastuzumab-induced antibody-dependent cell-mediated cytotoxicity T-ADCC in a lapatinib-resistant HER2 breast cancer cell line model., Annals Oncol., 28, (5), 2017, pp14 - 15Published Abstract, 2017, URL
Martinez VG, O'Driscoll L, Neuromedin U drives increased expression of TGF beta 1 in HER2-positive breast cancr cells and their extracellular vesicles: a novel biomarker of response to HER-targeted drugs., Cancer Research , 76, (14), 2016, pp116 - 117Published Abstract, 2016
Corcoran C, Rani S, Brown B, Crown J, O'Donovan N, O'Driscoll L, Extracellular miRNAs have potential as minimally-invasive biomarkers for predicting response to HER2-targeted agents, including Trastuzumab, as used in breast cancer , Cancer Research , Amer. Assoc. for Cancer Res. (AACR), April 2011, 71, 2011, pp4938 - 4939Published Abstract, 2011, DOI , URL
Germano S, Rani S, Kennedy S, Clynes M, Crown J, O'Driscoll L., Clinical significance and functional relevance of MAGED-4B in breast cancer. , Annals Oncol., 21, 2010, pp69 - 69Published Abstract, 2010
Eustace AJ, Mahgoub T, Kennedy S, Crown J, Larkin A, Tryfonopoulos D, O'Driscoll L, Clynes M, O'Donovan N., Targeting SRC kinase (SRC) in melanoma cells. , J. Clin. Oncol., 28, (15), 2010, pp8584 - 8586Published Abstract, 2010
Translating In Vitro Cell Lines result into Clinical Practice. in, editor(s)Hayat MA (ed.) , Methods of Cancer Diagnosis, Therapy, and Prognosis, Switzerland AG. , Springer Nature , 2010, pp183 - 191, [Mehta JP, O'Driscoll L, Barron N, Clynes M, Doolan P.]Book Chapter, 2010, URL
Tisdall AR, Rani S, Hennessy E, Wickham S, Dowling P, Bennett K, Abdin R, Wahab RA, Mcdermott JH, O'Driscoll L, Clynes M, Sreenan S. , Serum Messenger RNAs-Possible Biomarkers of Beta Cell Function in Diabetes Mellitus., Diabetes, American Diabetes Association , New Orleans, US, June 2009, 58, 2009, pp645 - 646Published Abstract, 2009, URL
Kennedy SM, Tracey D, Doolan P, Mehta JP, Clynes M, O'Driscoll L. , Correlation of the Gene Expression Profile of Primary Breast Carcinoma with Clinical Outcome., Lab. Invest., 98th Annual Meeting of the United States and Canadian Academy of Pathology., Harvard, Boston, US., March 2009, 58, 2009, pp645 - 646Conference Paper, 2009
Kennedy SM, Tracey D, Doolan P, Mehta JP, Clynes M, O'Driscoll L. , Correlation of the Gene Expression Profile of Primary Breast Carcinoma with Clinical Outcome., Modern Pathology, 22, 2009, pp50 - 50Published Abstract, 2009
O'Driscoll L, Doolan P, Clynes M., 'New assay for breast cancer comprises mRNA encoding markers, useful for diagnosing, prognosing, or predicting breast cancer.', Publ.of the Int.Appl. without Int.search REP. - World Intellectual Property Organization, WO2008132167-A2 ; WO2008132167-A3, 2011, 25 April 2008Patent, 2011, URL
Germano S, Clynes M, Kennedy S, Mehta JP, Kenny E, Ryan E, Doolan P, Gaminell P, Joyce H, Perez de Villarreall M, Hill A, O'Daly B, Linehan R, Cronin D, Daly C, Glynn S, O'Driscoll L., Novel role of neuronal Calcium Sensor-1 (NCS-1) as Prognostic Factor and Therapeutic Target in Breast Cance. , Anticancer Res., 28, (5), 2008, pp3290 - 3291Published Abstract, 2008
O'Driscoll L, O'Connor R, Clynes M.(ed.), Proceedings and abstracts of the International Conference on Global mRNA and Protein Analysis., Anticancer Res., 27, (3), t. Inst. Anticancer Res., 2007, 1-1235 pProceedings of a Conference, 2007
4. Rani S, Gately K, O'Byrne K, O'Driscoll L. , Circulating miRNA as minimally-invasive biomarkers for adenocarcinoma of the Lung. , J. Thoracic Oncol. , 14th World Conference on Lung Cancer. , Amsterdam, The Netherlands. , 6, (6), 2011, pp1036 - 1037Published Abstract, 2011
Lowry MC, Breslin S, O'Driscoll L., Investigating the roles of macrophage colony-stimulating factor (CSF1) and carbonic anhydrase 9 (CAIX) in neratinib-resistant HER2+ breast cancer cell lines and extracellular vesicles., J. Extracell. Vesicles., 7, (1), 2018, pp23 - 23Published Abstract, 2018, DOI , URL
Conlon NT, Lowry MC, Breslin S, O'Driscoll L, Eustace AJ, Crown J, O'Donovan N, Collins DM., Src inhibition overcomes neratinib-resistance in HER2-positive breast cancer., Expt. Mol. Therapeutics., Amer. Assoc. for Cancer Res. (AACR), Chicago, US, 78, (13), 2018, pp1834 - 1835Published Abstract, 2018, DOI
O'Driscoll L, Exosomal RNA as Cancer Biomarkers, "X International Society for Extracellular Vesicles Biomarker Workshop , New York, US, Sept 2012, 2012Oral Presentation, 2012
O'Neill, S. and Porter, R.K., McNamee, N. and Martinez, V.G. and O'Driscoll, L., 2-Deoxy-D-Glucose inhibits aggressive triple-negative breast cancer cells by targeting glycolysis and the cancer stem cell phenotype, Scientific Reports, 9, (1), 2019, p3788 - 3798Journal Article, 2019, DOI , URL , TARA - Full Text
Clayton A, Boilard E, Buzas EI, Cheng L, Falcón-Perez JM, Gardiner C, Gustafson D, Gualerzi A, Hendrix A, Hoffman A, Jones J, Lässer C, Lawson C, Lenassi M, Nazarenko I, O'Driscoll L, Pink R, Siljander PR, Soekmadji C, Wauben M, Welsh JA, Witwer K, Zheng L, Nieuwland R, Considerations towards a roadmap for collection, handling and storage of blood extracellular vesicles., J Extracellular Vesicles, 1, (8), 2019, p1647027 - 1647040Journal Article, 2019, DOI , URL , TARA - Full Text
Catalano M, O'Driscoll L, Inhibiting extracellular vesicles formation and release: a review of EV inhibitors., J Extracellular Vesicles, 9, (1), 2019, p1703244 - 1703258Journal Article, 2019, DOI , URL , TARA - Full Text
O'Driscoll L, Extracellular Vesicles From Mesenchymal Stem Cells as a Covid-19 Treatment , Drug Discovery Today, 2020, p[Epub ahead of print]Journal Article, 2020, DOI , URL , TARA - Full Text
Tsiapalis D, O'Driscoll L., Mesenchymal Stem Cell Derived Extracellular Vesicles for Tissue Engineering and Regenerative Medicine Applications , Cells, 9, (4), 2020, p991 - 1018Journal Article, 2020, DOI , URL , TARA - Full Text
Börger V, Weiss DJ, Anderson JD, Borràs FE, Bussloati B, Carter DRF, Dominici M, Falcón-Pérez JM, Gimona M, Hill AF, Hoffman AM, de Kleijn D, Levine BL, Lim R, Lötvall J, Mitsialis SA, Monguió-Tortajada M, Muraca M, Nieuwland R, Nowocin A, O'Driscoll L, Ortiz LA, Phinney DG, Reischl I, Rohde E, Sanzenbacher R, Théry C, Toh WS, Witwer KW, Lim SK, Giebel B., ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19, Cytotherapy, 2020Journal Article, 2020, DOI , URL
Eichholz KF, Woods I, Riffault M, Johnson GP, Corrigan M, Lowry MC, Shen N, Labour M, Wynne K, O'Driscoll L, Hoey DA., Human bone marrow stem/stromal cell osteogenesis is regulated via mechanically activated osteocyte-derived extracellular vesicles, Stem Cells Translational Medicine , 2020Journal Article, 2020, DOI , TARA - Full Text
O'Driscoll L, When E-Cadherin becomes unstuck in Cancer, New Eng, J. Medicine, 383, (9), 2020, p871 - 874Journal Article, 2020, DOI , URL
Soekmadji C, Li B, Huang Y, Wang H, An T, Liu C, Pan W, Chen J. Cheung L, Falcon-Perez JM, Song Gho Y, Holthofer HB, Le MT, Marcilla A, O'Driscoll L, Shekari F, Shen TL, Torrecilhas AC, Yan X, Yang F, Yin H, Xiao Y, Zhao Z, Zou X, Wang Q, Zheng L., The future of Extracellular Vesicles as Theranostics - an ISEV meeting report , J. Extracellular Vesicles, 9, (1), 2020Journal Article, 2020, DOI , URL , TARA - Full Text
Useckaite Z, Mukhopadhya A, Moran B, O'Driscoll L., Extracellular vesicles report on the MET status of their cells of origin regardless of the method used for their isolation., Scientific reports, 10, (1), 2020, p19020Journal Article, 2020, DOI , URL , TARA - Full Text
Daly R, O'Driscoll L., Extracellular vesicles in blood: are they viable as diagnostic and predictive tools in breast cancer?, Drug Discovery Today, 20, 2020, p30466 - 30469Journal Article, 2020, DOI , URL , TARA - Full Text
Anindya Mukhopadhya, Jessie Santoro, Barry Moran, Zivile Useckaite, Lorraine O'Driscoll , Optimisation and comparison of orthogonal methods for separation and characterisation of extracellular vesicles to investigate how representative infant milk formula is of milk, Food Chemistry, 353, 2021, p129309-Journal Article, 2021, DOI , URL
Miniaturized In Vitro In vitro Assays to Study Cellular Phenotypic Characteristics: Proliferation, Migration, Invasion, and Anoikis-Resistance in, editor(s)Smith S. (eds) , Methods Molecular Biology, Springer Nature , 2021, [McNamee N, O'Driscoll L.]Book Chapter, 2021, DOI , URL
Rankin-Turner, S. and Vader, P. and O'Driscoll, L. and Giebel, B. and Heaney, L.M. and Davies, O.G., A call for the standardised reporting of factors affecting the exogenous loading of extracellular vesicles with therapeutic cargos, Advanced Drug Delivery Reviews, 173, 2021, p479-491Journal Article, 2021, DOI , URL , TARA - Full Text
BÃ¶rger, V. and Weiss, D.J. and Anderson, J.D. and BorrÃ s, F.E. and Bussolati, B. and Carter, D.R.F. and Dominici, M. and FalcÃ³n-PÃ©rez, J.M. and Gimona, M. and Hill, A.F. and Hoffman, A.M. and de Kleijn, D. and Levine, B.L. and Lim, R. and LÃ¶tvall, J. and Mitsialis, S.A. and MonguiÃ³-Tortajada, M. and Muraca, M. and Nieuwland, R. and Nowocin, A. and O'Driscoll, L. and Ortiz, L.A. and Phinney, D.G. and Reischl, I. and Rohde, E. and Sanzenbacher, R. and ThÃ©ry, C. and Toh, W.S. and Witwer, K.W. and Lim, S.K. and Giebel, B., International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19, Cytotherapy, 22, (9), 2020, p482-485Journal Article, 2020, DOI , URL
Martinez-Pacheco S, O'Driscoll L, Evidence for the Need to Evaluate More Than One Source of Extracellular Vesicles, Rather Than Single or Pooled Samples Only, When Comparing Extracellular Vesicles Separation Methods, Cancers, 13, (16), 2021, p4021 - 4030Journal Article, 2021, DOI , URL , TARA - Full Text
Mukhopadhya A, Santoro J, O'Driscoll L, Extracellular vesicle separation from milk and infant milk formula using acid precipitation and ultracentrifugation, Star Protocols, 2, (4), 2021, p100821 - 100830Journal Article, 2021, DOI , URL , TARA - Full Text
McNamee N, Daly R, Crown J, O'Driscoll L, A method of separating extracellular vesicles from blood shows potential clinical translation, and reveals extracellular vesicle cargo gremlin-1 as a diagnostic biomarker, Transl. Oncol . , 15, (1), 2022, p1012 - 1020Journal Article, 2022, DOI , URL , TARA - Full Text
Martinez-Pacheco S, O'Driscoll L, Pre-Clinical In Vitro Models Used in Cancer Research: Results of a Worldwide Survey, Cancers, 13, (23), 2021, p6033 - 6041Journal Article, 2021, DOI , URL , TARA - Full Text
Witwer KW, Goberdhan DC, O'Driscoll L, Théry C, Welsh JA, Blenkiron C, Buzás EI, Di Vizio D, Erdbrügger U, Falcón-Pérez JM, Fu QL, Hill AF, Lenassi M, Lötvall J, Nieuwland R, Ochiya T, Rome S, Sahoo S, Zheng L, Updating MISEV: Evolving the minimal requirements for studies of extracellular vesicles, JEV, 10, (14), 2021, p12182 - 12190Journal Article, 2021, DOI , URL , TARA - Full Text
Santoro, J. and Mukhopadhya, A. and Oliver, C. and Brodkorb, A. and Giblin, L. and O'Driscoll, L., An investigation of extracellular vesicles in bovine colostrum, first milk and milk over the lactation curve, Food Chemistry, 401, (134029), 2023Journal Article, 2023, DOI , URL
McNamee, N. and de la Fuente, L.R. and Santos-Martinez, M.J. and Oâ Driscoll, L., Proteomics profiling identifies extracellular vesiclesâ cargo associated with tumour cell induced platelet aggregation, BMC Cancer, 22, (1), 2022Journal Article, 2022, DOI , URL
Papait, A. and Silini, A.R. and Gazouli, M. and Malvicini, R. and Muraca, M. and Oâ Driscoll, L. and Pacienza, N. and Toh, W.S. and Yannarelli, G. and Ponsaerts, P. and Parolini, O. and Eissner, G. and Pozzobon, M. and Lim, S.K. and Giebel, B., Perinatal derivatives: How to best validate their immunomodulatory functions, Frontiers in Bioengineering and Biotechnology, 10, (981061), 2022Journal Article, 2022, DOI , URL
Conlon, N. and Roche, S. and O'Neill, F. and Meiller, J. and Browne, A. and Breen, L. and O'Driscoll, L. and Cremona, M. and Hennessy, B. and Crown, J. and Collins, D., Neratinib plus dasatinib has pre-clinical efficacy against HER2-positive breast cancer, European Journal of Cancer, 174, 2022, pS64Journal Article, 2022, DOI , URL
Darragh, I.A.J. and Oâ Driscoll, L. and Egan, B., Exercise Training and Circulating Small Extracellular Vesicles: Appraisal of Methodological Approaches and Current Knowledge, Frontiers in Physiology, 12, (738333), 2021Journal Article, 2021, DOI , URL
McNamee N, Rodriguez de la Fuente L, Santos-Martinez MJ, O'Driscoll, Proteomics profiling identifies extracellular vesicles" cargo associated with tumour cell induced platelet aggregation, Cancer, 22, (1), 2022, p1023-Journal Article, 2022
Tao Zhang, Vilmar Bandero, Claire Corcoran, Ismael Obaidi, Manuel Ruether, John O'Brien, Lorraine O'Driscoll, Neil Frankish, Helen Sheridan, Design, Synthesis and Biological Evaluation of a Novel Bioactive Indane Scaffold 2-(diphenylmethylene) c-2, 3-dihydro-1H-inden-1-one with Potential Anticancer Activity, EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 188, (106529), 2023, p1 - 14, p1-14Journal Article, 2023
Shen N, Maggio M, Woods I, C Lowry M, Almasri R, Gorgun C, Eichholz KF, Stavenschi E, Hokamp K, Roche FM, O'Driscoll L, Hoey DA., Mechanically activated mesenchymal-derived bone cells drive vessel formation via an extracellular vesicle mediated mechanism., Journal of tissue engineering, 14, 2023, p20417314231186918Journal Article, 2023, DOI
Oliver, C. and Mishra, V.S.N. and Santoro, J. and Mukhopadhya, A. and Buckley, F. and O'Driscoll, L. and Giblin, L. and Brodkorb, A., Effect of In Vitro Enzyme Digestion and Bile Treatment on Milk Extracellular Vesicles Stability, Molecular Nutrition and Food Research, 68, (10), 2024Journal Article, 2024, DOI , URL
Welsh, J.A. and Goberdhan, D.C. and O'Driscoll, L. and ThÃ©ry, C. and Witwer, K.W., MISEV2023: An updated guide to EV research and applications, Journal of Extracellular Vesicles, 13, (2), 2024Journal Article, 2024, DOI , URL
Tsiapalis D, Floudas A, Tertel T, Boerger V, Giebel B, Veale D.J, Fearon U, Oâ Driscoll L, Therapeutic Effects of Mesenchymal/Stromal Stem Cells and Their Derived Extracellular Vesicles in Rheumatoid Arthritis, Stem Cells Translational Medicine, 12, (12), 2023, p849 - 862Journal Article, 2023, DOI
Lucien F, Gustafson D, Lenassi M, Li B, Teske J.J, Boilard E, von Hohenberg K.C, FalcÃ³n-Perez J.M, Gualerzi A, Reale A, Jones J.C, LÃ€sser C, Lawson C, Nazarenko I, O'Driscoll L, Pink R, Siljander P.R.M, Soekmadji C, Hendrix A, Welsh J.A, Witwer K.W, Nieuwland R, MIBlood-EV: Minimal information to enhance the quality and reproducibility of blood extracellular vesicle research, Journal of Extracellular Vesicles, 12, (12), 2023Journal Article, 2023, DOI
McNamee N, Catalano M, Mukhopadhya A, Oâ Driscoll L, An extensive study of potential inhibitors of extracellular vesicles release in triple-negative breast cancer, BMC Cancer, 23, (1), 2023Journal Article, 2023, DOI
Darragh I.A.J, McNamee N, Daly R, Pacheco S.M, O'Driscoll L, Egan B, The separation and identification of circulating small extracellular vesicles from endurance-trained, strength-trained and recreationally active men, Journal of Physiology, 601, (22), 2023, p5075 - 5091Journal Article, 2023, DOI
Darragh I.A.J, O'Driscoll L, Egan B, Within-Subject Variability and the Influence of Exercise Training History on the Resting Plasma Metabolome in Men, International Journal of Sport Nutrition and Exercise Metabolism, 33, (3), 2023, p141 - 150Journal Article, 2023, DOI
Mukhopadhya A, Tsiapalis D, McNamee N, Talbot B, Oâ Driscoll L, Doxorubicin Loading into Milk and Mesenchymal Stem Cellsâ Extracellular Vesicles as Drug Delivery Vehicles, Pharmaceutics, 15, (3), 2023Journal Article, 2023, DOI
Darragh I.A.J, Martinez-Pacheco S, O'Driscoll L, Egan B, Functional assays reflective of cancer hallmarks in BT-549 cells are not impacted by media supplemented with exercise-trained plasma, Experimental Physiology, 2023Journal Article, 2023, DOI
Conlon, N.T. and Roche, S. and Mahdi, A.F. and Browne, A. and Breen, L. and Gaubatz, J. and Meiller, J. and O'Neill, F. and O'Driscoll, L. and Cremona, M. and Hennessy, B.T. and Eli, L.D. and Crown, J. and Collins, D.M., Neratinib plus dasatinib is highly synergistic in HER2-positive breast cancer in vitro and in vivo, Translational Oncology, 49, (102073), 2024Journal Article, 2024, DOI , URL
Kennedy S, Clynes M, Doolan P, Mehta JP, Rani S, Crown J, O'Driscoll L., SNIP/p140Cap mRNA expression is an unfavourable prognostic factor in breast cancer and is not expressed in normal breast tissue., Brit. J. Cancer, 98, (10), 2008, p1641 - 1645Journal Article, 2008, DOI , URL , TARA - Full Text
Hennessy E, O'Driscoll L., Molecular medicine of microRNAs: structure, function and implications for diabetes., Expert Rev Mol Med. , 10, 2008, p1 - 20Journal Article, 2008, DOI , URL , TARA - Full Text
O'Driscoll L, Kenny E, Mehta JP, Doolan P, Joyce H, Gammell P, Hill A, O'Daly B, O'Gorman D, Clynes M., Feasibility and relevance of global expression profiling of gene transcripts in serum from breast cancer patients using whole genome microarrays and quantitative RT-PCR., Cancer Genomics Proteomics, 5, (2), 2008, p94 - 104Journal Article, 2008, URL , TARA - Full Text
Pierce A, Barron N, Linehan R, Ryan E, O'Driscoll L, Daly C, Clynes M., Identification of a novel, functional role for S100A13 in invasive lung cancer cell lines., Eur. J. Cancer, 44, (1), 2008, p151 - 159Journal Article, 2008, DOI , URL , TARA - Full Text
Dowling P, O'Driscoll L, Meleady P, Henry M, Roy S, Ballot J, Moriarty M, Crown J, Clynes M., 2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins., Electrophoresis, 28, (23), 2007, p4302 - 4310Journal Article, 2007, DOI , URL
Dowling P, Shields W, Rani S, Meleady P, Henry M, Jeppesen P, O'Driscoll L, Clynes M., Proteomic analysis of conditioned media from glucose responsive and glucose non-responsive phenotypes reveals a panel of secreted proteins associated with beta cell dysfunction., Electrophoresis, 29, (20), 2008, p4141 - 4149Journal Article, 2008, DOI , URL , TARA - Full Text
Martinez V, Kennedy S, Doolan P, Gammell P, Joyce H, Kenny E, Prakash Mehta J, Ryan E, O'Connor R, Crown J, Clynes M, O'Driscoll L., Drug metabolism-related genes as potential biomarkers: analysis of expression in normal and tumour breast tissue., Breast Cancer Res. Treat. , 110, (3), 2008, p521 - 530Journal Article, 2008, DOI , URL , TARA - Full Text
O'Connor R, Clynes M, Dowling P, O'Donovan N, O'Driscoll L., Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents., Expert Opin Drug Metab Toxicol. , 3, (6), 2007, p805 - 817Journal Article, 2007, DOI , URL , TARA - Full Text
Rani S, Clynes M, O'Driscoll L., Detection of amplifiable mRNA extracellular to insulin-producing cells: potential for predicting beta cell mass and function., Clin. Chem., 53, (11), 2007, p1936 - 1944Journal Article, 2007, DOI , URL , TARA - Full Text
Doolan P, Clynes M, Kennedy S, Mehta JP, Crown J, O'Driscoll L., Prevalence and prognostic and predictive relevance of PRAME in breast cancer, Breast Cancer Res. Treat. , 109, (2), 2008, p359 - 365Journal Article, 2008, DOI , URL , TARA - Full Text
O'Driscoll L, Walsh N, Larkin A, Ballot J, Ooi WS, Gullo G, O'Connor R, Clynes M, Crown J, Kennedy S., MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma., Anticancer Res., 27, 2007, p2115 - 2120Journal Article, 2007, URL , TARA - Full Text
McKiernan E, O'Driscoll L, Kasper M, Barron N, O'Sullivan F, Clynes M., Directed differentiation of mouse embryonic stem cells into pancreatic-like or neuronal- and glial-like phenotypes., Tissue Eng., 13, (10), 2007, p2419 - 2430Journal Article, 2007, DOI , URL
Roy S, Kenny E, Kennedy S, Larkin A, Ballot J, Perez De Villarreal M, Crown J, O'Driscoll L., MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer., Anticancer Res., 27, 2007, p1325 - 1330Journal Article, 2007, URL , TARA - Full Text
Mehta JP, O'Driscoll L, Barron N, Clynes M, Doolan P., A microarray approach to translational medicine in breast cancer: how representative are cell line models of clinical conditions?, Anticancer Res., 27, 2007, p1295 - 1300Journal Article, 2007, URL , TARA - Full Text
Mc Kiernan E, Barron NW, O'Sullivan F, Barham P, Clynes M, O'Driscoll L., Detecting de novo insulin synthesis in embryonic stem cell-derived populations., Exp. Cell Res. , 313, (7), 2007, p1405 - 1414Journal Article, 2007, DOI , URL , TARA - Full Text
O'Driscoll L., Extracellular nucleic acids and their potential as diagnostic, prognostic and predictive biomarkers., Anticancer Res., 27, (3), 2007, p1257 - 1265Journal Article, 2007, URL , TARA - Full Text
Keenan J, Pearson D, O'Driscoll L, Gammell P, Clynes M., Evaluation of recombinant human transferrin (DeltaFerrin(TM)) as an iron chelator in serum-free media for mammalian cell culture., Cytotech., 51, (1), 2006, p29 - 37Journal Article, 2006, DOI , URL , TARA - Full Text
O'Driscoll L, McMorrow J, Doolan P, McKiernan E, Mehta JP, Ryan E, Gammell P, Joyce H, O'Donovan N, Walsh N, Clynes M., Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays., Mol. Cancer, 5, 2006, p74 - 86Journal Article, 2006, DOI , URL , TARA - Full Text
O'Driscoll L., The emerging world of microRNAs., Anticancer Res., 26 , 2006, p4271 - 4278Journal Article, 2006, URL , TARA - Full Text
O'Driscoll L, Gammell P, McKiernan E, Ryan E, Jeppesen PB, Rani S, Clynes M., Phenotypic and global gene expression profile changes between low passage and high passage MIN-6 cells., J. Endocrinol. , 191, (3), 2006, p665 - 676Journal Article, 2006, DOI , URL , TARA - Full Text
Dowling P, O'Driscoll L, O'Sullivan F, Dowd A, Henry M, Jeppesen PB, Meleady P, Clynes M., Proteomic screening of glucose-responsive and glucose non-responsive MIN-6 beta cells reveals differential expression of proteins involved in protein folding, secretion and oxidative stress., Proteomics, 6, (24), 2006, p6578 - 6587Journal Article, 2006, DOI , URL , TARA - Full Text
O'Driscoll L, Clynes M., Biomarkers and multiple drug resistance in breast cancer., Curr. Cancer Drug Targets , 6, (5), 2006, p365 - 384Journal Article, 2006, DOI , URL , TARA - Full Text
Conway CM, O'Shea D, O'Brien S, Lawler DK, Dodrill GD, O'Grady A, Barrett H, Gulmann C, O'Driscoll L et al., The development and validation of the Virtual Tissue Matrix, a software application that facilitates the review of tissue microarrays on line., BMC Bioinformatics, 17, (7), 2006, p256 - 268Journal Article, 2006, DOI , URL , TARA - Full Text
O'Connor R, O'Leary M, Ballot J, Collins CD, Kinsella P, Mager DE, Arnold RD, O'Driscoll L, Larkin A, Kennedy S, Fennelly D, Clynes M, Crown J., A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer., Cancer Chemother Pharmacol. , 59, (1), 2007, p79 - 87Journal Article, 2007, DOI , URL , TARA - Full Text
O'Driscoll L, Clynes M., Molecular markers of multiple drug resistance in breast cancer., Chemotherapy, 52(3):125-9, (3), 2006, p125 - 129Journal Article, 2006, DOI , URL , TARA - Full Text
Larkin A, O'Driscoll L, Kennedy S, Purcell R, Moran E, Crown J, Parkinson M, Clynes M., Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study., Int. J. Cancer, 112, (2), 2004, p286 - 294Journal Article, 2004, DOI , URL , TARA - Full Text
O'Driscoll L, Gammell P, Clynes M., Mechanisms associated with loss of glucose responsiveness in beta cells., Transplant Proc. , 36, (4), 2004, p1159 - 1162Journal Article, 2004, DOI , URL , TARA - Full Text
O'Driscoll L, Cronin D, Kennedy SM, Purcell R, Linehan R, Glynn S, Larkin A, Scanlon K, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Clynes M., Expression and prognostic relevance of Mcl-1 in breast cancer., Anticancer Res., 24, (2), 2004, p473 - 482Journal Article, 2004, URL , TARA - Full Text
Liang Y, O'Driscoll L, McDonnell S, Doolan P, Oglesby I, Duffy K, O'Connor R, Clynes M., Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs., Int. J. Cancer, 111, (4), 2004, p484 - 493Journal Article, 2004, DOI , URL , TARA - Full Text
O'Driscoll L, Gammell P, Clynes M., Expression in murine teratocarcinoma F9 cells of transcription factors involved in pancreas development., Transplant Proc. , 36, (4), 2004, p1511 - 1518Journal Article, 2004, DOI , URL , TARA - Full Text
O'Driscoll L, Linehan R, M Kennedy S, Cronin D, Purcell R, Glynn S, W McDermott E, D Hill A, J O'Higgins N, Parkinson M, Clynes M., Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer., Cancer Lett., 201, (2), 2003, p225 - 236Journal Article, 2003, DOI , URL , TARA - Full Text
Clynes M, O'Connor R, O'Driscoll L, Daly C, Meleady P., Challenges in molecular analysis for individualized cancer therapy., Drug Discov. Today, 8, (12), 2003, p531 - 533Journal Article, 2003, DOI , URL , TARA - Full Text
Gammell P, O'Driscoll L, Clynes M., Characterisation of BHK-21 cells engineered to secrete human insulin, Cytotechnol., 41, (1), 2003, p11 - 21Journal Article, 2003, DOI , URL , TARA - Full Text
O'Driscoll L, Linehan R, Clynes M., Survivin: role in normal cells and in pathological conditions., Curr. Cancer Drug Targets , 3, (2), 2003, p131 - 152Journal Article, 2003, DOI , URL , TARA - Full Text
Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R, Clynes M., Prognostic importance of survivin in breast cancer., Br J. Cancer, 88, (7), 2003, p1077 - 1083Journal Article, 2003, DOI , URL , TARA - Full Text
O'Driscoll L, Linehan R, Liang YH, Joyce H, Oglesby I, Clynes M., Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro., Anticancer Res., 22, (6), 2002, p3117 - 3125Journal Article, 2002, URL , TARA - Full Text
O'Driscoll L, Gammell P, Clynes M., Engineering Vero cells to secrete human insulin, In Vitro Cell Dev. Biol. Anim. , 38, (3), 2002, p146 - 153Journal Article, 2002, DOI , URL , TARA - Full Text
Heenan M, O'Driscoll L, Cleary I, Connolly L, Clynes M., Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance., Int. J. Cancer, 71, (5), 1997, p907 - 915Journal Article, 1997, DOI , URL , TARA - Full Text
Finlay GA, O'Driscoll LR, Russell KJ, D'Arcy EM, Masterson JB, FitzGerald MX, O'Connor CM., Matrix metalloproteinase expression and production by alveolar macrophages in emphysema., Am. J. Respir. Crit. Care Med., 156, (1), 1997, p240 - 247Journal Article, 1997, DOI , URL , TARA - Full Text
Daly C, Coyle S, McBride S, O'Driscoll L, Daly N, Scanlon K, Clynes M., mdr1 ribozyme mediated reversal of the multi-drug resistant phenotype in human lung cell lines., Cytotechnol., 19, (3), 1996, p199 - 205Journal Article, 1996, URL , TARA - Full Text
O'Driscoll L, Kennedy S, McDermott E, Kelehan P, Clynes M., Multiple drug resistance-related messenger RNA expression in archival formalin-fixed paraffin-embedded human breast tumour tissue., Eur. J. Cancer, 32, (1), 1996, p128 - 133Journal Article, 1996, URL , TARA - Full Text
O'Driscoll L, Daly C, Saleh M, Clynes M., The use of reverse transcriptase-polymerase chain reaction (RT-PCR) to investigate specific gene expression in multidrug-resistant cells., Cytotechnol., 12, (1-3), 1993, p289 - 314Journal Article, 1993, URL , TARA - Full Text
Walsh N, Kennedy S, Larkin A, Roy S, Ooi W, Gullo G, Ballot J, Clynes M, Crown J, O'Driscoll L , MDR1/P-Glycoprotein and MRP-1 Protein Expression in Pancreatic (CaP) & Non-Small Cell Lung Cancers (NSCLC). , Ann. Oncol., 17, (9), 2006, p64 - 65Journal Article, 2006
Methods in Apoptosis in, Cell Biology: A Laboratory Handbook, International, Elsevier Academic Press, 2006, pp355 - 344, [O'Driscoll L, O'Connor R, Clynes M ]Book Chapter, 2006, DOI , URL , TARA - Full Text
Setting up a Cell Culture Laboratory in, editor(s)Julio E. Celis , Cell Biology: A Laboratory Handbook. 3rd Edition , Oxford, UK, Elsevier Academic Press, 2006, pp5 - 12, [O'Connor R, O'Driscoll L. ]Book Chapter, 2006, DOI , URL , TARA - Full Text
Germano S, Kennedy S, Hughes L, McDonnell S, Mehta JP, Doolan P, Clynes M, O'Driscoll L, Characterisation of Neuronal Calcium Sensor-1 (NCS-1) as a novel prognostic biomarker with potential therapeutic implications for triple negative breast cancer, Ann Oncol, 20, (2), Oxford Journals; Oxford University Press, 2009, pp49 - 50Meeting Abstract, 2009
Current Cancer Drug Targets, Bentham Science Publishers Ltd., 2009, -Critical Edition (Book), 2009, TARA - Full Text
Germano S, O'Driscoll L, Breast Cancer: Understanding Sensitivity and Resistance to Chemotherapy and Targeted Therapies to aid in Personalised Medicine, Curr Cancer Drug Targets, 9, (3), 2009, p398 - 418Journal Article, 2009, DOI , URL , TARA - Full Text
Collins DM, Crown J, O'Donovan N, Devery A, O'Sullivan F, O'Driscoll L, Clynes M, O'Connor R., Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines., Invest New Drugs, 28, (4), 2009, p433 - 444Journal Article, 2009, DOI , URL , TARA - Full Text
Walsh N, Larkin A, Kennedy S, Connolly L, Ballot J, Ooi W, Gullo G, Crown J, Clynes M, O Driscoll L., Expression of multidrug resistance markers ABCB1 (MDR-1/ Pgp) and ABCC1 (MRP-1) in renal cell carcinoma, BMC Urology, 24, (9), 2009, p6-Journal Article, 2009, DOI , URL , TARA - Full Text
P Doolan, M Clynes, S Kennedy, JP Mehta, S Germano, C Ehrhardt, J Crown, L O'Driscoll, TMEM25, REPS2 and Meis 1: Favourable prognostic and predictive biomarkers for breast cancer, Tumor Biol, 30, (4), 2009, p200-209Journal Article, 2009, DOI , URL
Walsh N, Kennedy S, Larkin AM, Tryfonopoulos D, Eustace AJ, Mahgoub T, Conway C, Oglesby I, Collins D, Ballot J, Ooi WS, Gullo G, Clynes M, Crown J, O'Driscoll L, Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis, British Journal of Cancer, 102, 2010, p1157-1162Journal Article, 2010, DOI , URL , TARA - Full Text
Hennessy E, Clynes M, Jeppesen P, O'Driscoll L, Identification of microRNAs with a role in glucose stimulated insulin secretion by expression profiling of MIN6 cells., Biochemical and Biophysical Research Communications, 396, (2), 2010, p457 - 462Journal Article, 2010, DOI , URL , TARA - Full Text
Lewis A Chodosh(ed.), Melanoma-associated antigen family protein-D4: clinical significance and functional relevance in breast cancer, Breast Cancer Research, 12, (1), 2010, 10-11 pProceedings of a Conference, 2010, DOI , URL , TARA - Full Text
Rani S, Mehta JP, Barron N, Doolan P, Jeppesen PB, Clynes M, O'Driscoll L, Decreasing Txnip mRNA and Protein Levels in Pancreatic MIN6 Cells Reduces Reactive Oxygen Species and Restores Glucose Regulated Insulin Secretion., Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 25, (6), 2010, p667-674Journal Article, 2010, DOI
O'Neill, AJ, Prencipe, M, Dowling, C, Fan, Y, Mulrane, L, Gallagher, WM, O'Connor, D, O'Connor, R, Devery, A, Corcoran, C, Rani, S, O'Driscoll, L, Fitzpatrick, JM, Watson, RWG, Characterisation and manipulation of docetaxel resistant prostate cancer cell lines, Molecular Cancer, 10, 2011, p126 - 135Journal Article, 2011, DOI , URL , TARA - Full Text
Friel AM, Corcoran C, Crown J, O'Driscoll L., Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer., Breast Cancer Res Treat. , 123, (3), 2010, p613 - 615Journal Article, 2010, DOI , URL , TARA - Full Text
Corcoran C, Friel AM, Duffy MJ, Crown J, O'Driscoll L., Intracellular and extracellular microRNAs in breast cancer., Clin Chem. , 57, (1), 2011, p18 - 32Journal Article, 2011, DOI , URL , TARA - Full Text
Rani S, O'Driscoll L., Reverse-transcriptase polymerase chain reaction to detect extracellular mRNAs., Methods Mol Biol. , 784, 2011, p15 - 25Journal Article, 2011, DOI , URL , TARA - Full Text
Hennessy E, O'Driscoll L., MicroRNA expression analysis: techniques suitable for studies of intercellular and extracellular microRNAs., Methods Mol Biol., 784, 2011, p99 - 107Journal Article, 2011, DOI , URL , TARA - Full Text
Germano S, O'Driscoll L., Western blotting analysis as a tool to study receptor tyrosine kinases., Methods Mol Biol. , 784, 2011, p109 - 121Journal Article, 2011, DOI , URL , TARA - Full Text
Sheridan H, Nestor C, O'Driscoll L, Hook I., Isolation, structure elucidation, and cytotoxic evaluation of furanonaphthoquinones from in vitro plantlets and cultures of Streptocarpus dunnii., J Nat Prod., 71, (1), 2011, p82 - 85Journal Article, 2011, DOI , URL , TARA - Full Text
Rani S, O'Brien K, Kelleher FC, Corcoran C, Germano S, Radomski MW, Crown J, O'Driscoll L., Isolation of exosomes for subsequent mRNA, MicroRNA, and protein profiling., Methods Mol Biol., 784, 2011, p181 - 195Journal Article, 2011, DOI , URL , TARA - Full Text
Germano S, Kennedy S, Rani S, Gleeson G, Clynes M, Doolan P, McDonnell S, Hughes L, Crown J, O'Driscoll L., MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis., International Journal of Cancer, 130, 2012, p1991 - 2002Journal Article, 2012, DOI , URL , TARA - Full Text
Chen X, Hermansen K, Xiao J, Bystrup SK, O`Driscoll L, Jeppesen PB. , Isosteviol has beneficial effects on palmitate-induced cell dysfunction and gene expression. , PLoS One , 7, (3), 2012, p34361 - 34369Journal Article, 2012, DOI , URL , TARA - Full Text
O'Connell K, Prencipe M, O'Neill A, Corcoran C, Rani S, Henry M, Meleady P, O'Driscoll L, Watson W, O'Connor R. , The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines. , Proteomics, 12, (13), 2012, p2115 - 2126Journal Article, 2012, DOI , URL , TARA - Full Text
Radziwon-Balicka A, Medina C, O'Driscoll L, Treumann A, Bazou D, Inkielewicz-Stepniak I, Radomski A, Jow H, Sawicki G, Radomski MW., Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. , Brit. J. Pharmacol., 167, (4), 2012, p787 - 804Journal Article, 2012, DOI , URL , TARA - Full Text
Walsh N, Kennedy S, Larkin A, Corkery B, O'Driscoll L, Clynes M, Crown J, O'Donovan N. , EGFR and HER2 inhibition in pancreatic cancer. , Invest. New Drugs, 31, (3), 2013, p558 - 566Journal Article, 2013, DOI , URL , TARA - Full Text
Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Sheikh R, Webb G, Mc Dermott R, Watson W, Crown J, O'Driscoll L. , Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. , PloS One, 7, (12), 2012, pe50999-51009Journal Article, 2012, DOI , URL , TARA - Full Text
Pierce A, McGowan PM, Cotter M, Mullooly M, O'Donovan N, Rani S, O'Driscoll L, Crown J, Duffy MJ , Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. , Cancer Biol Ther. , 14, (6), 2013, p537 - 545Journal Article, 2013, DOI , URL , TARA - Full Text
Breslin S, O'Driscoll L, 3-Dimensional cell culture: the missing link in drug discovery., Drug Discovery Today, 18, (5-6), 2013, p240 - 249Review Article, 2013, DOI , URL , TARA - Full Text
Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O'Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown J, Kennedy S, Clynes M. , Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis., Carcinogenesis, 34, (10), 2013, p2300 - 2308Journal Article, 2013, DOI , URL , TARA - Full Text
O'Brien K, Rani S, Corcoran C, Wallace R, Hughes L, Friel AM, McDonnell S, Crown J, Radomski MW, O'Driscoll L, Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. , Eur. J. Cancer, 49, (8), 2013, p1845 - 1859Journal Article, 2013, DOI , URL , TARA - Full Text
Jella KK, Rani S, O'Driscoll L, McClean B, Byrne HJ, Lyng FM. , Exosomes are involved in mediating radiation induced bystander signaling in human keratinocyte cells. , Radiat. Res. , 181, (2), 2014, p138 - 145Journal Article, 2014, DOI , URL , TARA - Full Text
Hill AF, Pegtel DM, Lambertz U, Leonardi T, O'Driscoll L, Pluchino S, Ter-Ovanesyan D, Nolte-'t Hoen EN. , ISEV position paper: extracellular vesicle RNA analysis and bioinformatics. , J. Extracell. Vesicles., 2013, p22859-Review Article, 2013, DOI , URL , TARA - Full Text
Receptor tyrosine kinases and drug resistance: development and characterization of in vitro models of resistance to RTK inhibitors. in, editor(s)O'Driscoll L , Meth. Mol. Biol., 2015, pp169 - 180, [Corcoran C, O'Driscoll L]Book Chapter, 2015, DOI , URL , TARA - Full Text
Receptor tyrosine kinase targeting in multicellular spheroids. in, editor(s)O'Driscoll L , Meth. Mol. Biol., 2015, pp161 - 168, [Breslin S, O'Driscoll L]Book Chapter, 2015, DOI , URL , TARA - Full Text
Eustace AJ, Kennedy S, Larkin AM, Mahgoub T, Tryfonopoulos D, O'Driscoll L, Clynes M, Crown J, O'Donovan N, Predictive biomarkers for dasatinib treatment in melanoma , Oncoscience, 1, (2), 2014, p158 - 166Journal Article, 2014, DOI , URL , TARA - Full Text
Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J, O'Driscoll L, miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer , Mol. Cancer, 13, 2014, p71 - 79Journal Article, 2014, DOI , URL , TARA - Full Text
Analysis of changes in phosphorylation of Receptor Tyrosine Kinases: antibody arrays in, editor(s)O'Driscoll L , Meth. Mol. Biol., 2015, pp15 - 23, [Rani S, O'Driscoll L]Book Chapter, 2015, DOI , URL , TARA - Full Text
O'Driscoll L, Rani S, Marker and Target for Responsiveness and Resistance to Cancer Agents, 2011, WO2013057323Patent, 2011, URL
O'Driscoll L, O'Byrne K, LUNGMARK, 2011, US20130059742Patent, 2011, URL
Corcoran C, Rani S, O'Driscoll L, miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression., The Prostate, 74, (13), 2014, p1320 - 1334Journal Article, 2014, DOI , URL , TARA - Full Text
Rani S, Gately K, Crown J, O'Byrne K, O'Driscoll L, Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma., Cancer Biology & Therapy, 14, (12), 2013, p1104 - 1112Journal Article, 2013, DOI , URL , TARA - Full Text
Rani S, Corcoran C, Shiels L, Germano S, Breslin S, Madden S, McDermott MS, Browne BC, O'Donovan N, Crown J, Gogarty M, Byrne AT, O'Driscoll L, Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors., Cancer Research, 74, (14), 2014, p3821 - 3833Journal Article, 2014, DOI , URL , TARA - Full Text

Corcoran S, Rani S, O'Brien K, O'Neill A, Watson W, Crown J, O'Driscoll L. , The use of in vitro cell line models to investigate docetaxel-resistance in prostate cancer., Ir. J. Med. Sci. , 2011, 180, 2011, pp287 - 288Published Abstract
Rani S, Germano S, Kennedy S, Gleeson G, Clynes M, Doolan P, McDonnell S, Hughes L, Crown J, O'Driscoll L. , Investigating clinical and functional relevance of MAGE-D4B in breast cancer. , Ir. J. Med. Sci. , 180, 2011, pp295-Published Abstract
Springer London(ed.), Royal Academy of Medicine in Ireland, Irish Journal of Medical Science, Brookfield Health Sciences Complex, Univeristy College Cork, 185, (Suppl. 1), 20/06/2013, Springer London Ltd, 236 Gray's Inn Road, London, 2013, S32-33 pProceedings of a Conference
Springer London(ed.), Royal Academy of Medicine in Ireland, Irish Journal of Medical Science, Brookfield Health Sciences Complex, Univeristy College Cork, 185, (Suppl. 1), 20/06/2013, Springer London Ltd, 236 Gray's Inn Road, London, 2016, S21 pProceedings of a Conference
Coakley, R., O'Neill, S., Coakley, R., Glynn, P., O'Neill, S., Finlay, G.A., Russell, K.J., McMahon, K., D'Arcy, E.M., Masterson, J.B., Fitzgerald, M.X., O'Connor, C.M., O'Driscoll, L.R., Finlay, G.A., Fitzgerald, M.X., O'Connor, C.M., McGarvey, L.P.A., Forsythe, P., Heaney, L.G., MacMahon, J., Ennis, M., Leonard, C., Tormey, V., Burke, C.M., Poulter, L.W., Keatings, V.M., FitzGerald, M.X., Barnes, P.J., Harty, H.R., Corfield, D.R., Adams, L., Schwartzstein, R.M., Kiely, J.F., Buckley, A., Shiels, P., Deegan, P.C., Maurer, B., McNicholas, W.T., Dunlop, K.A., Martin, B., Riley, M., Shields, M.D., Glynn, P., Kilgallen, I., Coakley, R., O'Neill, S., McElvaney, N.G., Cervantes-Laurean, D., Wehr, N., Gabriele, K., Robinson, W., Moss, J., Levine, R.L., Urbach, V., Walsh, D., Harvey, B., McElroy, M.C., Pittet, J.-F., Allen, L., Wiener-Kroonish, J., Dobbs, L.G., O'Donnell, D.M., McMahon, K.J., O'Connor, C., Fitzgerald, M.X., McGuirk, P., Mahon, B., Griffin, F., Mills, K.H.G., Murphy, R., Brijker, F., Mulloy, E., Cohen Tervaert, J.W., Walshe, J., O'Neill, S., McGarvey, L.P.A., Heaney, L.G., Lowry, R.C., Shepherd, D.R.T., MacMahon, J., Gamble, L.A., Carton, C., Memon, R., Winter, D., Chan, A., Aherne, T., O'Reilly, P., Harbison, J.A., McNicholas, W.T., O'Callaghan, S., Mulloy, E., Keane, M., McKenna, M., Woods, S., O'Neill, S., Lamon, A., Leonard, C., Faul, J., Murphy, M., Burke, C.M., Tormey, V., Riley, M., Porszasz, J., Engelen, M.P.K.J., Brundage, B., Wasserman, K., Sweeney, M., O'Regan, R.G., McLoughlin, P., Sweeney, M., Honner, V., Sinnott, B., O'Regan, R.G., McLoughlin, P., Kilgallen, I., O'Neill, S., McGrath, D.S., Kiely, J., Cryan, B., Bredin, C.P., McGrath, D.S., Shortt, C., Stack, M., Kelleher, N., Bredin, C.P., Russell, K.J., McRedmond, J., Mulkerji, N., Keatings, V., Fitzgerald, M.X., O'Connor, C.M., Boylan, G.M., McElroy, M.C., Dobbs, L.G., Forsythe, P., McGarvey, L.P.A., Cross, L.J.M., Ennis, M., Heaney, L.G., MacMahon, J., Davern, S., O'Connor, C.M., McDonnell, T.J., Kiely, J.L., Lawless, G., Cunningham, S., McNicholas, W.T., Lordan, J., Clancy, L., Manning, P., Plunkett, P., Donaghy, D., Kiely, J., McDonnell, T.J., Ben Musbah, F., Loftus, B.G., Ben Musbah, F., Loftus, B.G., Rutherford, R., Watson, S.N.E., Gilmartin, J.J., Henry, M., Mullins, G., Brennan, N., Kiely, J.L., Deegan, P.C., McNicholas, W.T., Irish Thoracic Society - Proceeds of Annual Scientific meeting, November, 1996, Irish Journal of Medical Science, 167, (9 Supplement), 1998, p1-13Journal Article
Tormey WP (ed.)(ed.), Royal Academy of Medicines Ireland, Irish Journal of Medical Science, University College Cork, Ireland, 185, June 2013, 2013, 32-33 pProceedings of a Conference
Rani S, Mehta JP, Barron N, Doolan P, Clynes M, Jeppessen PB, O'Driscoll L., TXNIP-identified as a regulator of glucose-stimulated insulin secretion and reactive oxygen species in MIN6 cells., Ir. J. Med. Sci. , 179, (7), 2010, pp290 - 291Published Abstract
O'Driscoll L, Expression microarray analysis in human cancer., Anticancer Res., 27, (3), 2007, pp1371 - 1372Published Abstract
Oglesby I, Clynes M, O'Driscoll L., Optimisation of siRNA transfection and its use in characterising the role of novel targets in a range of human carcinoma cell lines., Anticancer Res., 27, (3), 2007, pp1384 - 1385Published Abstract
RTE, 'RTE Six-One and Nine o'clock news', 2016, -Broadcast
EU Commission/H2020, 'European Network on Microvesicles and Exosomes in Health & Disease', https://youtu.be/TmQBS5rPyEY, 2018, -Broadcast
Rani S, Germano S, Kennedy S, Gleeson G, Clynes M, Doolan P, McDonnell S, Hughes L, Crown J, O'Driscoll L. , Investigating MAGE-D4B function in tumorigenesis and its potential as therapeutic target in breast cancer. , J Pharm. Pharmaceut. Sci. , Pharmacy Conference, Dublin, 14, (3), 2011, pp205 - 2018Published Abstract
Corcoran C, Rani S, Browne B, Crown J, O'Donovan N, O'Driscoll L. , The pursuit of miRNAs as minimally-invasive biomarkers predictive of response to anticancer treatment for HER2-positive breast cancer., J Pharm. Pharmaceut. Sci., 14, (3), 2011, pp205 - 218Published Abstract
O'Driscoll L, miR-134 transported in extracellular vesicles reduces triple-negative breast cancer aggression, International Society for Extracellular Vesicles (ISEV) 2014, De Deolen, Rotterdam Conference Centre, the Netherlands, 1 May, 2014Oral Presentation
O'Driscoll L, Targeted Therapies for Breast cancer: the Highs and Lows beyond their Discovery, 9th International Cancer Conference, Trinity Biomedical Sciences Institute, TCD, 17 September, 2014Invited Talk
Breslin S, O'Driscoll L, Investigating the role of neuronal calcium sensor-1 in acquired HER2 drug-resistance, 9th International Cancer Conference, Trinity Biomedical Sciences Institute, TCD, 18 September, 2014Poster
O'Driscoll L, The relevance of exosomes in breast cancer , Microvesicles & Exosomes in Health and Disease, Univ. of Palermo, Sicily, Italy, 27 September, 2014Invited Talk
Breslin S, Daly M, O'Donovan N, Crown J, O'Driscoll L, The potential of Neuromedin U as a biomarker in HER2-overexpressing breast cancer, Irish Association of Cancer Research Annual Meeting 2015, Castletroy Park Hotel, Limerick, 26 February, 2015Poster
O'Driscoll L, What we can learning from studying Extracellular Signals in Cancer, Extracellular Vesicles in Health & Disease Meeting, University of Helsinki, Finland, 08 April, 2015Invited Talk
O'Driscoll L, MEET-THE-EXPERT: Exosomes as Diagnostics and Prognostics (Clinical importance of exosomes and microvesicles research in Europe), International Society for Extracellular Vesicles (ISEV) 2015, Washington DC, US, 26 April, 2015Invited Talk
O'Driscoll L, Keynotes Speaker: Exosomes and Ectosomes in the Sub-types of Breast Cancer, Exosomes and Ectosomes in Health & Disease, Porto University, Portugal, 28 September, 2015Invited Talk
O'Driscoll L, Exosomes and Ectosomes: our friends or foes in cancer?, Tumour Liquid Biopsy Symposium, Universitatsklinikum Freiburg, Germany, 29 October, 2015Invited Talk
O'Driscoll L, Exosomes, their miRNAs and Cancer, MicroRNAs & Genome Editing, Cambridge University, UK, 2 November, 2015Invited Talk
Daly M, O'Driscoll L, Potential alternatives to gold standard ultracentrifugation for extracellular vesicle isolation, UK Extracellular Vesicles Forum, Cardiff University, UK, 15 December, 2015Poster
Lowry MC, O'Brien K, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RAF, O'Driscoll L, miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity, UK Extracellular Vesicles Forum, Cardiff University, UK, 15 December, 2015Poster
Lowry M, O'Driscoll L, Extracellular vesicle studies identify miR-134 as a potential biomarker and novel therapeutic target for breast cancer, Irish Association of Cancer Research Annual Meeting 2016, Kingsley Hotel, Cork, 26 February, 2016Poster
Lowry MC, O'Brien K, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RAF, O'Driscoll L, miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity, Breast-Predict Midway Point Showcase, University College Dublin, 31 March, 2016Oral Presentation
Lowry MC, O'Brien K, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RAF, O'Driscoll L, miR-134 in breast cancer-derived extracellular vesicles: potential biomarker and therapeutic option, Faculty of Health Sciences Research Day, Trinity Biomedical Sciences Institute, TCD, 15 September, 2016Poster
Lowry MC, O'Brien K, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RAF, O'Driscoll L, Extracellular Vesicle studies identify the potential diagnostic relevance of miR-134 as a biomarker for triple negative breast cancer and as a potential therapeutic option, 10th International Cancer Conference, Trinity Biomedical Sciences Institute, TCD, 18 October, 2016Oral Presentation
Daly M, O'Driscoll L, Investigating potential alternatives to "gold standard" ultracentrifugation for exosomes isolation, European network on microvesicles and exosomes in health and disease (ME-HaD) training course "Extracellular Vesicles & Exosomes: Analysis and Properties", University of Ioannina, Greece, 2 March, 2016Oral Presentation
Daly M, O'Driscoll L, Circulating Exosomes: is there a high-throughput method comparable to the gold-standard ultracentrifugation for their isolation?, 38th All Ireland Schools of Pharmacy Research Conference, Royal College of Surgeons in Ireland, Dublin, 21 March, 2016Poster
Daly M, O'Driscoll L, Comparison of high-throughput methods for extracellular vesicle isolation to "gold standard" ultracentrifugation, Faculty of Health Sciences Research Day, Trinity Biomedical Sciences Institute, TCD, 15 September, 2016Poster
O'Driscoll L, Keynotes Speaker: Extracellualr Vesicles in Breast Cancer - kill the messenger?, Microvesicles and Exosomes in Health and Disease, University of Ioannina, Greece, 4 March, 2016Invited Talk
O'Driscoll L, MEET-THE-EXPERT: Extracellular Vesicle as Modulators of Drug Resistance and Tumor Metastasis, 5th International Meeting of the International Society for Extracellular Vesicles (ISEV), De Deolen, Rotterdam Conference Centre, the Netherlands, 3 May, 2016Invited Talk
O'Driscoll L, The influence of Exosomes and Ectosomes in Cancer, Hypoxia and Angiogenesis, Weatherall Institute of Molecular Medicine, University of Oxford, UK, June, 2016Invited Talk
O'Driscoll L, Extracellular Vesicles: Biological & Therapeutic Potential, Extracellular Vesicles 2016, University of Cambridge, UK, 12 July, 2016Invited Talk
O'Driscoll L, Cancer Research: the Future is Now, Five Year Celebration of Trinity Biomedical Sciences Institute, TBSI, TCD, 5 September, 2016Invited Talk
Lowry MC, O'Brien K, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RAF, O'Driscoll L, miR-134 in Breast Cancer-derived Extracellular Vesicles, Irish Association of Pharmacologists (IAP) conference 2016, Royal College of Surgeons in Ireland, Dublin, 30 November, 2016Oral Presentation
Lowry MC, Breslin S, Toomey S, Hennessy BT, O'Driscoll L, Investigation of mechanisms of neratinib-resistance in HER2-overexpressing Breast Cancer, Irish Association of Cancer Research Annual Meeting 2017, Newpark Hotel, Kilkenny, 22-24 February, 2017Poster
Lowry MC, Breslin S, Toomey S, Hennessy BT, O'Driscoll L, Insights into the mechanisms of neratinib-resistance: investigating a possible role for EVs in HER2-overexpressing breast cancer, International Society for Extracellular Vesicles (ISEV) 2017, Toronto, Canada, 17-21 May, 2017Oral Presentation
O'Driscoll L, HER2-targeted drug resistance is associated with immune evasion in cancer cells and their derived EVs, International Society for Extracellular Vesicles (ISEV) 2017, Toronto, Canada, 17-21 May, 2017Oral Presentation
O'Driscoll L, Microvesicles and Exosomes in Health and Disease, International Society for Extracellular Vesicles (ISEV) 2017, Toronto, Canada, 17-21 May, 2017Invited Talk
O'Driscoll L, Extracellular Vesicles (EVs) and Therapy, 24th Meeting of the EAU Section of Urological Research (ESUR), Institut Curie, Paris, France, 13 October, 2017Invited Talk
O'Driscoll L, Exosomes and Ectosomes: important Players in the Liquid Biopsy, Inaugural Cancer Research Club, University College Dublin, 21 November, 2017Invited Talk
O'Driscoll L, Keynotes Speaker: Exosomes and Ectosomes - friends & foes in cancer?, Dublin City University Research Day, Dublin City University, 26 January, 2018Invited Talk
O'Driscoll L, Characterisation and analysis of exosomes/extracellular vesicles, American Physiological Society: President's Symposium Series, San Diego, US, 22 April, 2018Invited Talk
O'Driscoll L, Training in Extracellular Vesicles: for benefit in Health & Disease, International Society for Extracellular Vesicles (ISEV) 2018, Barcelona, Spain, 3 May, 2018Invited Talk
O'Driscoll L, Exosomes and Ectosomes in Breast (and other) Cancers, 10th International Symposium on Translational Research in Oncology, Herbert Park Hotel, Dublin, 27-29 September, 2017Invited Talk
O'Driscoll L, Exosomes and Microvesicles: our Friends or Foes in Cancer?, European Research Night, Trinity Biomedical Sciences Institute, TCD, 28 September, 2017Invited Talk
Rani S, Germano S, Kennedy S, Crown J, O'Driscoll L, Clinical significance and functional relevance of melanoma-associated antigen family protein-D4 (MAGED-4) in breast cancer, European Discover Research Night, Dublin, 27 September, 2013Oral Presentation
Rani S, O'Brien K, O'Donovan N, Crown J, O'Driscoll L, Role of exosome in acquired resistance to HER-targeted therapies in breast cancer, Microvesicles and Exosomes in Health and Disease, Herbert Park Hotel Dublin, 17 May, 2013Oral Presentation
Rani S, O'Brien K, O'Donovan N, Crown J, O'Driscoll L, Exosome-mediated response to HER-targeted therapies in breast cancer, IACR, Dublin, 27 February-1 March, 2013Oral Presentation
Rani S, O'Driscoll L, Neuromedin U: a novel target to overcome resistance to HER-targeted therapies and a potential predictive biomarker, TBSI Research Day, Trinity Biomedical Sciences Institute, TCD, 18 September, 2012Oral Presentation
Rani S, Germano S, Kennedy S, Gleeson G, Clynes M, Doolan P, McDonnell S, Hughes L, Crown J, O'Driscoll L, Investigating clinical and functional relevance of MAGE-D4B in Breast cancer, Royal Academy of Medicine in Ireland and Biomedical Sciences Annual Meeting, Royal College of Surgeons in Ireland, Dublin [Awarded Barcroft Medal], 22 June, 2011Oral Presentation
Rani S, Germano S, Kennedy S, Clynes M, Crown J, O'Driscoll L, MAGE-D4B in Breast Cancer: assessment of Intracellular & Extracellular relevance, MTCI Breast Cancer Symposium, Dublin, November, 2010Oral Presentation
Rani S, Mehta JP, Doolan P, Barron N, Jeppesen PB, Clynes M, O'Driscoll L, Txnip-identified as a regulator of glucose-stimulated insulin secretion and reactive oxygen species in MIN6 cells, "Translational Research": Applying molecular insights from laboratory discovery to clinical care, Ireland, 23-24 June, 2010Oral Presentation
Rani S, Germano S, Madden S, Corcoran C, Breslin S, O'Brien N, McDermott M, Browne B, O'Donovan N, Crown J, O'Driscoll L, Neuromedin U: a potential predictive biomarker for HER2-targeted drugs, American Society for Clinical oncology (ASCO) Annual Meeting, Chicago, US, 1-5 June, 2012Poster
Rani S, Germano S, Madden S, Corcoran C, Breslin S, O'Donovan N, Crown J, O'Driscoll L, Neuromedin U expression is associated with resistance to HER2-targeted therapies and poor prognosis in breast cancer patients, Irish Association for Cancer Research Annual (IACR) meeting, Culloden Hotel, Belfast, 29 February-2 March, 2012Poster
Rani S, O'Brien K, McDonnell S, Hughes L, Friel AM, Radomski MW, Crown J, L O'Driscoll, Triple-negative breast cancer cells can transfer phenotypic characteristics via exosomes, The European Multidisciplinary Cancer Congress (ESMO), Stockholm, Sweden, 23-27 September, 2011Poster
Rani S, Gately K, O'Byrne K, O'Driscoll L, Circulating miRNA as minimally-invasive biomarkers for adenocarcinoma of the Lung, 14th World Conference on Lung Cancer, Amsterdam, The Netherlands, 3-7 July, 2011Poster
Rani S, Gately K, O'Byrne K, O'Driscoll L, The relevance of circulating miRNAs as minimally-invasive biomarkers for non-small cell lung cancer, Pharmacy Conference, Dublin, University College Dublin, 2011Poster
Rani S, O'Brien K, Friel A, Kelleher FC, Crown J, O'Driscoll L, Investigating the potential of circulating exosomes and their miRNA contents as minimally-invasive biomarkers for triple negative breast cancer, Irish Association for Cancer Research, Cork, 2-4 March, 2011Poster
Rani S, O'Brien K, Friel A, O'Driscoll L, Exosomal miRNA as circulating biomarker in Triple Negative Breast Cancer, Breakthrough Triple Negative Breast Cancer, London, 9-11 March, 2011Poster
Breslin S, Rani S, Corcoran C, O'Brien K, O'Driscoll L, Effects of acquired neratinib-resistance in breast cancer cell line variants, IACR, Dublin, 27 February-1 March, 2013Poster
Barry S, Rani S, O'Driscoll L, Investigating acquired resistance to targeted anti-cancer agents in breast cancer, 2nd Year Medicine Research Poster Symposium, Department of Pharmacology and Therapeutics, Trinity College Dublin, 2011Poster
O'Brien K, Rani S, Friel AM, Kelleher FC, Crown J, Radomski MW, O'Driscoll L, Circulating exosomes in triple negative breast cancer: are these treasure chests of minimally-invasive biomarkers?, All Ireland Schools of Pharmacy Conference, Royal College of Surgeons, Dublin, 2011Poster
O'Brien K, Rani S, McDonnell S, Hughes L, Radomski MW, O'Driscoll L, Investigating naturally-occurring circulating nano-sized exosomes in cancer, All Ireland Schols of Pharmacy Conference, Royal College of Surgeons, Dublin, 2011Oral Presentation
Corcoran C, Rani S, Browne B, Crown J, O'Donovan N, O'Driscoll L, Identification of intracellular and extracellular miRNAs in SKBR3 and its Herceptin-resistant variant with potential as predictive biomarkers for breast cancer, EMBO|EMBL Symposium: Non-Coding Genome, October, 2010Poster
Corcoran C, Rani S, Browne B, Crown J, O'Donovan N, O'Driscoll L, Extracellular miRNAs have potential as minimally-invasive biomarkers for predicting response to HER2-targeted agents, including Trastuzumab, as used in breast cancer, 102nd Amer. Assoc. for Cancer Res. (AACR) annual meeting, Orlando, Florida, US, 2-6 April, 2011Poster
Germano S, Rani S, Kennedy S, Clynes M, Crown J, O'Driscoll L, Clinical significance and functional relevance of MAGED-4B in breast cancer, 35th ESMO Congress, Milan, Italy, October, 2010Poster
Germano S, Rani S, Kennedy S, Crown J, Clynes M, O'Driscoll L, Melanoma-associated antigen family protein-D4 (MAGED-4): clinical significance and functional relevance in breast cancer, Breast Cancer Research, London, UK, 18 May, 2010Poster
Germano S, Rani S, O'Driscoll L, Melanoma-associated antigen family protein-D4B (MAGE-D4B) as a novel prognostic biomarker and therapeutic target for breast cancer, Advances in Cancer Research: From the Laboratory to the Clinic, Jordan, 7-10 March, 2010Poster
Lowry MC, Breslin S, Conlon NT, Collins D, Eustace A, Crown J, Maher S, O'Sullivan J, O'Driscoll L, Investigating the role of CAIX in the mechanism of HER2-targeted drug resistance in breast cancer cells and extracellular vesicles , Breast-Predict showcase, UCD, Dublin, 17 October, 2018Oral Presentation
Lowry MC, Breslin S, O'Driscoll, Investigating the role of CSF-1 and CAIX in neratinib-resistant HER2+ breast cancer cell lines and extracellular vesicles, International Society for Extracellular Vesicles (ISEV) 2018, Barcelona, Spain, 2-6 May, 2018Oral Presentation
Lowry MC, Breslin S, Toomey S, Hennessy BT, O'Driscoll L, Investigating the mechanism of neratinib-resistance in HER2-overexpressing breast cancer, Irish Association of Pharmacologist Annual Conference 2017, Royal College of Surgeons in Ireland, Dublin, 30 November, 2017Oral Presentation
O'Driscoll L, 3D Cell Cultures in Drug Discovery, 18th International Pharmaceutical Technology Symposium, Hacettepe University, Ankara, Turkey, September, 2016Invited Talk
O'Driscoll L, Keynotes Speaker: Innovations in Cancer Research, CIBIO, Trento, Italy, February, 2016Invited Talk
O'Driscoll L, Intracellular & Extracellular Biomarkers associated with Breast Cancer, Frye Halloran Symposium, Harvard University, US, 5 November, 2009Invited Talk
O'Driscoll L, The many forms of & many treatments for Breast Cancer, Cancer Awareness, 20 January, 2010Invited Talk
O'Driscoll L, Extracellular Vesicles in Triple-Negative Breast Cancer, Institut Curie, INSERM U932, Paris, France, 28 July, 2013Invited Talk
O'Driscoll L, European Consortium on Microvesicles and exosomes in Health and Disease, Annual EU FP7 Co-operation Science & Technology Chairs Conference, Malta, 29 April, 2014Invited Talk
O'Neill S, Bohl M, Hokamp K, Gregersen S, Hermansen K, O'Driscoll L, Potential miRNA biomarkers for metabolic syndrome, RAMI Annual meeting 2014, University College Dublin, 19 June, 2014Oral Presentation
O'Driscoll L, Identification of Circulating Nucleic Acids in Metabolic Syndrome, Annual DairyHealth Meeting, Aalborg, Sweden, 2 April, 2014Invited Talk
O'Neill S, Bohl M, Hokamp K, Gregersen S, Hermansen K, O'Driscoll L, Circulating miRNAs in Metabolic Syndrome and the Effect of Dietary Intervention on these miRNAs, Young Life Scientists Ireland (YLSI) Conference 2014, Trinity Biomedical Sciences Institute, TCD, 1 March, 2014Poster
Breslin S, Corcoran C, Rani S, O'Driscoll L, Acquired neratinib-resistance in breast cancer cells induces cross-resistance to HER-targeting drugs through a mechanism mediated by Hsp90, IGF1R, Bcl2 and caspase-8, Irish Association for Cancer Research (IACR) Annual Conference, Galway, 27 February, 2014Poster
O'Driscoll L, RNAs and Exosomes as Biomarkers and Potential Therapeutic Targets for Breast Cancer, 3rd World Breast Cancer Congress, Shanghai, China, 25 April, 2010Invited Talk
Breslin S, Rani S, Corcoran C, O'Brien K, O'Driscoll L, Better ways of assessing anti-cancer drugs in the laboratory to increase their success for breast cancer patients, All Ireland Schools of Pharmacy Conference, University College Cork, 2012Poster
Breslin S, Rani S, Corcoran C, O'Brien K, O'Driscoll L, Generation and characterisation of neratinib-resistant breast cancer cell line variants, EORTC-NCI-AACR Symposium, Dublin, 2012Poster
Breslin S, O'Driscoll L, Investigating the development of neratinib-resistance in HER2-overexpressing breast cancer cells, All Ireland Schools of Pharmacy Conference, Queen's University Belfast, 2013Oral Presentation
Breslin S, O'Driscoll L, Investigating the effects and putative mechanism of acquired resistance to neratinib in breast cancer, Annual meeting of the Biomedical Sciences section of RAMI, 2013Oral Presentation
Breslin S, O'Driscoll L, Potential use of extracellular vesicles as diagnostic or predictive biomarkers for breast cancer, Eu COST BM1202 Microvesicles and Exosomes in Health and Disease (MEHAD), Helsinki, Finland, 2015Oral Presentation
Daly M, O'Driscoll L, Investigating potential alternatives to "gold standard" ultracentrifugation for exosomes isolation, Irish Association for Cancer Research (IACR) Annual Meeting, Kingsley Hotel, Cork, 26 February, 2016Poster
O'Neill S, Bohl M, Gregersen S, Hermansen K, O'Driscoll L, Extracellular vesicles, extracellular vesicles-contained miRNAs and total miRNAs as plasma-based biomarkers for metabolic syndrome, International Society for Extracellular Vesicles (ISEV) 2016, Rotterdam, The Netherlands, 5 May, 2016Oral Presentation
O'Neill S, Bohl M, Gregersen S, Hermansen K, O'Driscoll L, Circulating miRNA biomarkers for metabolic syndrome and obesity and their link with triple negative breast cancer, All Ireland Schools of Pharmacy Conference, Queen's University Belfast, 30 March, 2015Oral Presentation
O'Neill S, Bohl M, Hokamp K, Gregersen S, Hermansen K, O'Driscoll L, Circulating miRNAs: potential biomarkers for metabolic syndrome, All Ireland Schools of Pharmacy Conference, TCD, 14 April, 2014Oral Presentation
Corcoran C, O'Brien K, O'Driscoll L, MicroRNAs as Biomarkers & Therapeutics Targets for Cancer, Dublin microRNA Day, O'Callaghan Stephen's Green Hotel, Dublin, 29 May, 2013Oral Presentation
Corcoran C, Rani S, O'Brien A, O'Neill A, O'Brien K, Prencipe M, Crown J, Watson W, O'Driscoll L, Exosomes - potential mediators of prostate cancer progression?, Irish Association for Cancer Research Annual Meeting, Culloden Hotel, Belfast, 29 February-2 March, 2012Oral Presentation
Corcoran C, Rani S, O'Brien K, O'Neill A, Watson W, O'Driscoll L, Investigating the mechanisms of Docetaxel-resistance in prostate cancer, All Ireland Schools of Pharmacy Conference 2011, Royal College of Surgeons, Dublin, 18-19 April, 2011Oral Presentation
Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, McDermott R, Watson W, Crown J, O'Driscoll L, Prostate cancer progression: Do Exosomes play a role?, All Ireland Schools of Pharmacy Conference 2012, University College Cork, 1-2 April, 2012Poster
Corcoran C, Rani S, O'Brien A, O'Neill A, O'Brien K, Prencipe M, Crown J, Watson W, O'Driscoll L, The relevance of exosome secretion in prostate cancer and their potential to confer docetaxel-resistance to secondary cells, 103rd Annual Meeting of the American Association for Cancer Research, Chicago, Illinois, US, 31 March-4 April, 2012Poster
O'Driscoll L., Interview by HBM-LS (Lonza), 2018, -Miscellaneous, URL
O'Neill S, O'Driscoll L, Metabolic Syndrome & Cancer, 36th National Pharmacy Conference, Hamilton Building, TCD, 14 April, 2014Oral Presentation
Breslin S, O'Driscoll L, The effects of acquired neratinib-resistance on HER2-overexpressing breast cancer cells, TBSI Annual Symposium, Trinity Biomedical Sciences Institute, TCD, 9 May, 2014Oral Presentation
Rani S, O'Driscoll L, NCS-1 and acquired drug resistance in HER2-overexpressing breast cancer cells, 36th National Pharmacy Conference, Hamilton Building, TCD, 14 April, 2014Oral Presentation
O'Brien K, O'Driscoll L, Exosomes in TNBC, Triple negative breast cancer meeting, St. Vincent's University Hospital, 2013Oral Presentation
O'Brien K, O'Driscoll L, Functional characterisation, profiling and therapeutic manipulation of breast cancer derived exosomes, Research seminar, Institut Curie, Paris, 2013Oral Presentation
O'Brien K, O'Driscoll L, Exosomal miRNAs in triple-negative breast cancer progression and treatment, Dublin microRNA Day, Dublin, 2013Oral Presentation
O'Brien K, O'Driscoll L, Harnessing exosomes/microvesicles as microRNA therapeutic delivery vesicles in triple-negative breast cancer, European network on microvesicles and exosomes in health and disease (ME-HAD) inaugural meeting, Trinity College Dublin, 2013Oral Presentation
O'Brien K, O'Driscoll L, Exosomal miRNAs in triple-negative breast cancer, All Ireland Schools of Pharmacy Conference, University of Ulster, Belfast, 2013Oral Presentation
O'Brien K, O'Driscoll L, Exosomal miRNAs: potential communicators in triple-negative breast cancer, Irish Association for Cancer Research Annual Meeting, Dublin, 2013Oral Presentation
O'Brien K, O'Driscoll L, Can triple-negative breast cancer cells transfer aggressive phenotypic characteristics via exosomes?, Scientific advisory board review of MTCI, Dublin, 2012Oral Presentation
O'Brien K, O'Driscoll L, The relevance of triple-negative breast cancer-derived exosomes in the transfer of aggressive phenotypic characteristics, All Ireland Schools of Pharmacy Conference, University College Cork, 2012Oral Presentation
O'Brien K, O'Driscoll L, Assessing the influence of exosomes in triple-negative breast cancer, Irish Association for Cancer Research Annual Meeting, Belfast, 2012Oral Presentation
O'Brien K, O'Driscoll L, Triple-negative breast cancer cells can transfer phenotypic characteristics via exosomes, Exosomes and Microvesicles, Orlando, Florida, US, 2011Oral Presentation
O'Brien K, O'Driscoll L, The Relevance of Exosomal-miRNAs in Triple-negative Breast Cancer Progression, International Society for Extracellular Vesicles annual scientific meeting, Boston, MA, US, 2013Poster
O'Brien K, O'Driscoll L, Can Exosomes influence Triple-negative breast cancer metastasis?, International Society for Extracellular Vesicles (ISEV) 2012, Gothenburg, Sweden, 2012Poster
Corcoran C, Rani S, Breslin S, Ghobrial IM, Crown J, O'Driscoll L, The potential of miR-630 , an IGF1R regulator, as a predictive biomarker for HER2-targeted drugs, American Society for Clinical Oncology Annual Meeting, Chicago, Illinois, US, 31 May-4 June, 2013Poster
Corcoran C, Rani S, O'Brien K, O'Neill A, Prencipe M, Watson W, Crown J, O'Driscoll L, Exosomes - potential regulators and biomarkers of prostate cancer progression, International Society for Extracellular Vesicles (ISEV) 2012, Gothenburg, Sweden, 18-21 April, 2012Poster
Corcoran C, Rani S, O'Brien K, Crown J, O'Driscoll L, Establishing and Characterising New in Vitro models of Docetaxel-resistance in Prostate Cancer, The European Multidisciplinary Cancer Congress, Stockholm, Sweden, 23-27 September, 2011Poster
O'Driscoll L, Role of Exosomes in cancer cell communication, dissemination and resistance to therapy, "X European Society for Human Genetics Annual Conference, Paris, France, June, 2013Invited Talk
O'Driscoll L, Metabolic Syndrome and Cancer, "X Metabolic Syndrome and Cancer Workshop, Skagen, Denmark, June, 2013Invited Talk
O'Driscoll L, Exosomes as Diagnostics and Predictive Biomarkers in Cancer, Biomarkers & Diagnostics World Congress, Philadelphia, US, May, 2013Invited Talk
O'Driscoll L, KEYNOTES TALK: Cancer: the eXosome factor, "X International conference on Exosomes & Biomarkers in Cancer, University of Colorado at Denver, US, April, 2012Invited Talk
O'Driscoll L, Our Quest for Tumour Biomarkers and New Therapeutic Targets , University of Colorado School of Pharmacy Seminar Series, April, 2012Invited Talk
Dr. Claire O'Connell (author/Science Correspondent) writing about Prof. O'Driscoll's research, Cancer signals in the blood, 2013, -Miscellaneous

Research Expertise

Bi-directional translational research; cancer research; diagnostic biomarkers; predictive/ companion markers; novel therapeutic targets; targeted therapies; pipeline drugs; monoclonal antibodies; small molecules; breast cancer; lung cancer; prostate cancer; G.I. cancer; melanoma; pancreatic cancer; brain cancer; multiple resistance; metastasis/ advanced cancer; immune suppression; exosomes; hypoxia; extracellular vesicles; clinical and industry collaborations; public and patient involvement; clinical trials

Title

Characterisation of 2 Novel mRNAs Present in Breast Tumours - but not Normal Breast Tissue - with potential as Therapeutic Targets & Diagnostic/Prognostic Biomarkers.

Summary

We have identified, using whole genome expression microarray analysis of a large bank of breast cancer and normal breast biopsies, two novel poorly characterised transcripts which do not occur in normal breast but are found in more than one third of breast cancer biopsies. Kaplan-Meier, X2 and Cox Regression analyses showed that expression of each of these transcripts is significantly associated with poor prognosis. We propose to characterise and investigate the function of these two genes, which were not present in previously published microarray analyses, in order to assess their possible importance in breast cancer cell biology, as therapeutic targets and as diagnostic/prognostic/predictive markers. In this project, we propose to isolate and sequence the full length cDNAs, and to investigate homologies to better characterised genes with known roles within the cell. We will investigate the functions of these genes in relation to properties such as cell growth rate, cell survival, cell division, invasion, drug resistance and soft agar colony formation, in a panel of breast cancer cell lines using cDNA and SiRNA transfections. qRT-PCR will be used to choose cell lines most appropriate for up- or down-regulation of expression. Peptides from the predicted protein structure will be used to raise antibodies for Western Blotting and immunocytochemistry. GFP-tagged cDNAs will be prepared in order to investigate subcellular localisation of the gene products. By analogy with the her2/herceptin diagnostic/therapeutic pairing, we hope this project may lead to identification of new specific targets for diagnosis and therapy of subsets of breast carcinoma patients.

Funding Agency

Health Research Board

Date From

October 2006

Date To

March 2010
Title

Biomarkers of Response to Taxotere in Hormone-Refractory Prostate Cancer

Summary

The standard of care for hormone refractory prostate cancer (HRPC) is taxotere (generally 2-3 weekly; for 10 cycles). This treatment increases overall survival (OS) by, on average, 2.5 months. Mechanisms are not currently available to determine (i) those patients who are most suitable/would benefit from this treatment; (ii) why this benefit is short-term (why relapse/resistance occurs); and (iii) which patients are unlikely to respond to taxanes and so should potentially be offered targeted therapies. The primary objective is to establish if gene expression in circulating tumour cells (CTC) from HRPCs patients is predictive of response to therapy.

Funding Agency

Adnagen

Date From

Jan 2008

Date To

Dec 2010
Title

Extracellular Vesicles Promoted Regenerative Osseointegration (EVPRO)

Summary

This project, as part of the consortium programme entitled "Extracellular Vesicles Promoted Regenerative Osseointegration (EVPRO)" is a collaboration with the Fraunhofer, Aachen, Germany and 9 other European academic, clinical and industry partners that will develop EV-loaded hydrogel coatings with immunomodulatory activity for promoted regenerative osseointegration of revision endoprosthesis. The focus in the O'Driscoll group is on developing and optimising a down-stream process to isolate EVs released from mesenchymal stem cells (MSC-EVs), evaluating potency assays to assess the anti-inflammatory / immunomodulatory capacities of obtained MSC-EVs to modulate endoprosthesis induces inflammation processes, elucidating the molecule contents of MSC-EVs with the intention of identifying those that may be contributing beneficial effects, and transferring the MSC-EVs production process to GMP compliant conditions.

Funding Agency

EU Commission - Horizon 2020 (H2020)

Date From

Jan. 2019

Date To

Feb. 2023
Title

Exploring the Relevance of Exosomes in Cancer

Summary

Funding Agency

IRCSET

Date From

Oct 2011

Date To

Sept 2014
Title

European Network on Microvesicles & Exosomes in Health and Disease

Summary

Microvesicles and Exosomes (ME) have attracted much recent interest because of their potential functions, use as disease biomarkers and possible therapeutic exploitation. Due to their enormous relevance, through nationally-funded projects throughout Europe, this relatively new field of research is quickly expanding. There are, however, many associated issues that need to be addressed to ensure optimal research performance and collation and cross-interpretation of data. These issues range from the need to derive a consensus on fundamental guidelines/nomenclature and optimal techniques for vesicle isolation and analysis, to more advanced issues such as collating emerging data and expertise towards better understanding, and thus exploiting, the physiological and pathological roles of ME. There is also urgency to identify gaps in ME knowledge and how best collaborative research can address these questions. This Consrtium creates a network of European experts, fostering a multidisciplinary approach to enhance both basic understanding and translational potential of ME.

Funding Agency

EU H2020

Date From

Jan 2013

Date To

Dec 2018
Title

Extracellular Vesicles from Mesenchymal Stem Cells as a Treatment Option for COVID-19

Summary

Funding Agency

COVID19 Response Funding

Date From

June 2020
Title

Breast-PREDICT

Summary

Breast-PREDICT is a country-wide collaboration between experts in the area of breast cancer research, funded by the Irish Cancer Society. This 'virtual Centre' was launched in October 2013 and will run for a period of five years. Breast-PREDICT brings together researchers from six academic institutions across Ireland: UCD, TCD, RCSI, DCU, NUIG and UCC, and a nationwide clinical trials group, ICORG. We collect information and tumour samples from nearly every breast cancer patient in the country, with their consent. Using these valuable resources, we will improve our understanding of how this disease can spread and become resistant to treatment, and find ways to combat this with new and better therapies. This is a multi-disciplinary Centre, which unites breast cancer experts with different skills, to work towards a common goal.

Funding Agency

Irish Cancer Society

Date From

Nov. 2013

Date To

Oct. 2018
Title

New Diagnostic and Prognostic Biomarkers for Age-Related Macular Degeneration

Summary

Funding Agency

IRCSET

Date From

Oct 2010

Date To

Sept 2013
Title

Milking extracellular vesicles for improved infant milk formula (MilkEV)

Summary

My research group has found human breast milk and cows milk contain tiny sacs called EVs. Their studies suggest EVs would not be destroyed in the gut and may be absorbed into the bloodstream. When infants suckle, EVs are believed to help build up their immune system. MilkEV's first objective is to investigate differences between human and cows milk EVs and see if any EV loses during infant milk formula (IMF) manufacture can be prevented or restored. The second objective is to further evaluate milk EVs as protective "delivery vehicles" for oral administration. The intended benefits include helping to design best possible IMF. This is of societal importance and of economic relevance too, given that ~10% of the world's IMF is manufactured in Ireland. MilkEV should also help progress towards delivery of beneficial substances (e.g. biotherapeutics) that would otherwise be destroyed in the gut (595,014).

Funding Agency

Dept. of Agriculture, Food and Marine (DAFM)

Date From

July 2018

Date To

June 2022
Title

Exosomal Neuromedin U and miR-X: potential predictive biomarkers for HER2-targeted drugs

Summary

A new range of anti-cancer drugs have become available that are used to treatment some breast cancer patients. The best known one is Herceptin (trastuzumab), but there are other new drugs in this family. These drugs were designed to interact with HER2, a molecule found at greater amounts on cancer cells compared to normal cells for ~25% of breast cancer patients. These drugs are more cancer-specific than older chemotherapy and can offer advantages of greatly helping many patients without causing serious side-effects. Unfortunately, some patients who seem suitable candidates based on the HER2 test, don't benefit from these treatments. Some others respond at first, but then become unresponsive (resistant) to the treatment. Added to the problem of some patients not benefiting, these drugs are extraordinarily expensive costs to healthcare. We urgently need ways of predicting which patients with "HER2 tumours" are likely to benefit. We also need to be able to overcome the resistance problem. Studying cells from breast tumours, we recently found two molecules, NmU and miR-X, at substantially different amounts both inside and outside cells that are resistant to these drugs compared to those that are sensitive. By "tweaking" their amounts in the cells, we can make cells more resistant or more sensitive to these drug; suggesting that this approach might help overcome the serious resistance problem in tumours. So, (i) we explained this study to many patients enrolling in clinical trials using these drugs. They donated blood specimens that we want to test to see if analyse for NmU and miR-X can predict those who will/won't respond; (ii) we are at a stage where we now need to progress our work of "tweaking" NmU and miR-X to see if we can help overcome this resistance in a living organism.

Funding Agency

Health Research Board

Date From

Feb. 2014

Date To

Feb. 2017
Title

Biomarkers (mRNAs, miRNAs, proteins) for Type 1 & Type 2 Diabetes

Summary

Type 2 diabetes mellitus (T2DM) is associated with reduced β-cell function, relatively reduced β-cell mass and insulin resistance. Serum biomarkers of β-cell mass and/or function have not been described. Amplifiable mRNAs, which have been detected in conditioned medium from cultures of insulin-producing animal cell-lines, if detectable in human serum, could serve as markers of β-cell mass. We attempted to detect these mRNAs in serum from patients with newly diagnosed T2DM and compared them to healthy controls. We recruited T2DM subjects (mean DM duration 4.36±2.33 months) and controls (age, gender and BMI matched). Medical history, physical exam and fasting bloods were obtained. Serum mRNA levels were analysed using real time quantitative reverse transcription-PCR. Two mRNAs, thioredoxin interacting protein (Txnip) and early growth response factor 1 (Egr1), previously associated with cell-line glucose responsiveness, were detected.Levels of Egr1 were lower and levels of Txnip tended to be higher in T2DM. Egr1 level correlated positively with smoking history in pack-years (ρ=0.485, p=0.042), total (ρ=0.554, p=0.017) and LDL cholesterol (ρ= 0.495, p= 0.043). Txnip level correlated positively with age (ρ= 0.471, p=0.042) and HOMA%S (ρ= 0.489, p= 0.034) but not with smoking history or cholesterol level. To our knowledge, this is a first description of detectable serum mRNAs possibly linked to the diagnosis of diabetes. Significance of this finding is unclear at present and confounding variables may have an effect on these results.

Funding Agency

Higher Education Authority & Seed Funding

Date From

Oct 2008

Date To

Jan 2011
Title

Lungmark

Summary

Discovery & validation of panels of new diagnostic and theranostic blood-Based biomarkers for lung cancer

Funding Agency

Enterprise Ireland (under National Strategic Dev. Plan 2007-2013 co-financed by ERDF)

Date From

5 Oct 2009

Date To

31 March 2011
Title

Biomarkers & Therapeutics Targets: MeS, Diabetes and Cancer

Summary

In vitro, in vivo and clinical trials studies including researchers from ireland, Denmark, The Netherlands, and Germany to identify and validate biomarkers & new therapeutics targets of potential relevant to metabolic syndrome, diabetes and cancer

Funding Agency

Danish Strategic Research Council / EU

Date From

March 2013

Date To

Feb. 2016
Title

Marie Keating Foundation PhD Scholarship at Trinity College Dublin

Summary

Better ways of assessing anti-cancer drugs in the laboratory to increase their success for breast cancer patients

Funding Agency

Marie Keating Foundation, Trinity Foundation, TCD

Date From

April 2011

Date To

March 2015
Title

Marie Keating Foundation PhD Scholarship at Trinity College Dublin

Summary

Developing blood tests for earlier diagnosis & optimal treatment selection for breast cancer patients

Funding Agency

Marie Keating Foundation, Trinity Foundation, TCD

Date From

Jan 2010

Date To

Jan 2015
Title

Molecular Therapeutics for Cancer

Summary

This Cluster of scientific, clinical, industrial partners, with support from the All Ireland Clinical Oncology Research Group (ICORG) focusses on Molecular Therapeutics for Cancer. This fully-integrated translational cancer drug discovery and development programme will significantly benefit cancer patients. Our industry patners include SRC's Industry Partners are GlaxoSmithKline, Pfizer, Merck Sharpe & Dohme, Novartis, Roche, and Amgen. SFIs support for this SRC is 7.3m.

Funding Agency

Science Foundation Ireland (SFI)

Date From

Oct 2009

Date To

Sept 2014
Title

Extracellular vesicles: training in extracellular vesicles for benefit in health and disease (TRAIN-EV)

Summary

Exosomes and microvesicles/ectosomes, collectively termed extracellular vesicles (EV), have attracted much recent interest because of their potential functions, use as disease biomarkers and possible therapeutic exploitation. Due to their enormous relevance, this relatively new field of research is quickly expanding. However, there are still many gaps in knowledge that need to be addressed to ensure optimal exploitation of EVs from health and Europe's economic benefit. Addressing this, TRAIN-EV's objective is to provide excellent and integrated multi-disciplinary and inter-sectoral training of a critical mass of ESRs of outstanding potential in the academic, clinical, and industry/business components of exploiting EV, while performing novel cutting-edge research to address these gaps and generate new knowledge. This will be achieved by appointing 15 PhD students with Beneficiary and Partner Organisations offering secondments, training and additional networking opportunities. --- 3,900,500

Funding Agency

EU Commission - Horizon 2020 (H2020)

Date From

2017

Date To

2021
Title

3D Printed Extracelluar Vesicles for in situ Bone Tissue Regeneration

Summary

Stem cell therapy can repair bone defects caused by trauma or resection of cancerous tumors. Stem cells secrete small packages called extracellular vesicles (EVs) which are thought to be involved in this healing. The objective of this innovative research is to develop implants comprised of EVs and biomaterials to heal bones. Cutting-edge technology will permit the fabrication of implants to exactly fit the shape of the patient's broken bones. Since this is a cell-free, off-the shelf therapy, it will reduce pain since it won't require a bone or bone marrow harvest, be less expensive, and available to more patients, compared to stem cell therapy.

Funding Agency

Science Foundation Ireland

Date From

Dec 2019

Date To

Nov 2023
Title

Extracellular Vesicles in Cancer (EVIC)

Summary

EVIC is a project about tiny particles that are released from cancer cells into the bloodstream. These are called extracellular vesicles or EVs for short. Building on discoveries by Prof. O'Driscoll and her team, EVIC will study how EVs can be used for the early diagnosis of cancer and as indicators of the optimum anti-cancer drugs for a patient. Their research also shows that EVs from cancer cells may play a role in the spread of cancer throughout the body and in making cancer cells not respond to treatment. EVIC will investigate a new way of stopping, or at least limiting, this happening. But not all EVs are bad! EVIC will also engineering EVs from safe healthy cells to help transport drugs directly to cancer cells, so as to be of benefit at lowest possible doses with fewest side-effects.

Funding Agency

Irish Research Council

Date From

Sept. 2019

Date To

Sept. 2023

Pharmacology and pharmaceutical sciences, Genetics, Cancer, Other basic medicine and life sciences,

Recognition

Pfizer Young Investigator International Award 1991
Elected Member of the Royal Irish Academy (MRIA) 2021
Dublin City University's President's Targeted Research Award 2006
MA (jure oficii) 2012
Irish Research Council Advanced Laurate Award 2019
Royal College of Physicians National Scientific & Medical Award 1996
Albert College Fellowship Award 2004
Elected Fellow of the Royal Society for Biology (FRSB) 2020
Elected Fellow of Trinity College Dublin (FTCD) 2012
Eurolife Distinguished Lecture Award 2019

Member, European Society for Medical Oncology (ESMO)
Founding Committee Member, Irish Association of Pharmacologists (IAP) present
Member of the Academy of Pharmaceutical Scientists
Member, European Assoication for Cancer Research (EACR)
Board Member of the National Institute for Cellular Biotechnology 2008
Member, Royal Academy of Medicine in Ireland
Director, Irish Association for Cancer Research (IACR) 2014
Deputy-President of the Irish Branch of the European Tissue Culture Society (ETCS) 2010
Invited Member of the International Institute of Anticancer Research (IIAR) Scientific Advisory Board present
Member, American Society for Cancer Research (AACR)
Member of the National Institute for Cellular Biotechnology Scientific Advisory Board 2008
Elected Member on Dublin City University's Research Advisory Board 2008
Member of British Pharmacological Society present
Invited Member of Irish Cancer Society (ICS) Research Capacity Building Committee 2013
Elected Member of the Board of Directors, International Society for Extracellular Vesicles (ISEV) present
Member, American Society for Clinical Oncology (ASCO)
Member of the European Association for Cancer Research (EACR) present
Member of Irish Network of Stem-Cell Investigators (INNSI) 2010
Elected Member on Dublin City University's Faculty of Science & Health Research Committee 2008
Founding Chair, European Network on Microvesicles and Exosomes in Health and Disease present

Scientific PI, Trinity St. James's Cancer Institute (TSJCI) Breast Cancer Programme 2018
Editorial Board Member, PeerJ 2012
Hospital Professional Awards: Judging Panel Member 2014
Appointed as Strand Leader, Irish Cancer Society (ICS)-funded national virtual research centre Breast-Predict 2013
Editorial Board Member, BMC Cancer 2011
External Examinder for 35 PhD candidates including studenst in: Oxford Univeristy, Cambridge University, Aarhus University, Edinburgh University, Cardiff University, University College London, Queen's University Belfast, Royal College of Surgeons of Ireland, National University of Ireland Galway, University College Dublin, Univeristy College Cork 2005
Research Specialist: All Ireland Clinical Oncology Research Group/Cancer Trials Ireland (& Principal Investigator on Phase I & II cancer clinical trials) 2005
Scientific Advisory Board (SAB) Member of ProEvLifeCycle, The Netherlands 2019
Founding Director, European Consortium TRAIN-EV (extracellular vesicles: for benefit in health and disease). 2017
Editorial Board Member for Cancer Genomics & Proteomics 2006
Examiner (Report and Site Visit) for Enterprise Ireland Applied Research Capability award to Dundalk Institute of Technology 2013
Management Committee member, Irish Cancer Society (ICS)-funded national virtual cancer research centre Breast-Predict 2013
Management Committee member, Science Foundation Ireland-funded national virtual cancer research centre Molecular Therapeutics for Cancer Ireland 2009
External Examiner/Panel Member to Athlone Institute of Technology for Higher Education and Training Awards Council (HETAC) 2006
Chair, International Society for Extracellular Vesicles (ISEV) Annual Conference 2021 2020-2021
Academic Mentor, Trinity College Dublin 2016
Editorial Board Member, Journal of Biomarkers 2012
Mentor, Career Path Development, University College Los Angeles (UCLA) 2011
Member of the European Federation of Pharmaceutical Scientists 2016
Cancer Theme Steering Committee member, Trinity College Dublin 2012
Editorial Board Member, J. Extracell. Ves. 2013
Management Committee member, H2020-funded cooperation in science and technology: Delivery of Antisense RNA Therapeutics 2017
External Examiner to Aarhus University postgraduate degree programmes 2010
Guest-Editor of book volume of Current Cancer Drug Targets entitled "Mechanisms of Cancer Drug Sensitivity & Resistance: A Translational Approach" 2009
Chair, International Society for Extracellular Vesicles (ISEV) Annual Conference 2022 2021-2022
Invited Role Model, Inspiring Leadership - Leadership Foundation for Higher Education (Aurora), Ireland and UK 2016
Strategic Advisory Board (SAB) Member, Midatech Ltd, Oxford 2014
Editorial Board Member, Molecular Biotechnology 2010
Invited Role Model, Inspiring Leadership - Leadership Foundation for Higher Education (Aurora), Ireland and UK 2016
Guest-Edition of Methods in Molecular Biology: Gene Expression Profiling - 2nd Edition 2018
Management Committee member, H2020-funded cooperation in science and technology: Identifying Biomarkers through Translational Research for Prevention and Stratifictaion of Cancer 2018
Honorary Secretary to Science and Meetings Committee, International Society for Extracellular Vesicles 2018
Editorial Board Member, Anticancer Research 2009
Editorial Board Member for Encyclopaedia of Bioscience Frontier in Bioscience 2007
Frequently review for journals incl. Oncogene, Eur. J. Cancer, J. Medical Virol., Tissue Eng., J. Histochem. Cytochem., Stem Cells, Anticancer Res., Exp. Opin. Drug Discovery, BMC Development Biology, Diabetes, Obesity & Metabolism, Cancer Detect. Prevent., The Review of Diabetes Studies, Cancer Genomics & Proteomics, Differentiation, FEBS Lett., Exp. Opin. Mol. Diag., Eur. J. Pharmaceutical Sci, Experimental Haematol., Personalized Medicine, Circulation Res., Biochemica Medica, Cancer, Eur. J. Pharmacol., Leukaemia Res., Biochem. Pharmacol., Exp. Opin. Therap. Targets, J. Pharmacy & Pharmacol., Brit. J. Dermatol., Clin. Chem., BBA Cancer, Cancer Res., Nature, Nature Medicine, The Lancet 2001
Guest-Edition of Methods in Molecular Biology: Gene Expression Profiling 2009
Molecular and Precision Oncology Theme Leader, Trinity St. James's Cancer Institute (TSJCI) 2019
Founding Committee Member, Irish Association of Pharmacologists (IAP) 2016
Editorial Board Member, PeerJ 2012
Scientific PI, Trinity St. James's Cancer Institute (TSJCI) Breast Cancer Programme 2018
Hospital Professional Awards: Judging Panel Member 2014
Honorary Secretary to Science and Meetings Committee, International Society for Extracellular Vesicles 2018
Research Specialist: All Ireland Clinical Oncology Research Group/Cancer Trials Ireland (& Principal Investigator on Phase I & II cancer clinical trials) 2005
Appointed as Strand Leader, Irish Cancer Society (ICS)-funded national virtual research centre Breast-Predict 2013
Editorial Board Member, BMC Cancer 2011
External Examinder for 35 PhD candidates including studenst in: Oxford Univeristy, Cambridge University, Aarhus University, Edinburgh University, Cardiff University, University College London, Queen's University Belfast, Royal College of Surgeons of Ireland, National University of Ireland Galway, University College Dublin, Univeristy College Cork 2005
External Examiner/Panel Member to Athlone Institute of Technology for Higher Education and Training Awards Council (HETAC) 2006
Chair, International Society for Extracellular Vesicles (ISEV) Annual Conference 2021 2020-2021
Editorial Board Member for Cancer Genomics & Proteomics 2006
Mentor, Career Path Development, University College Los Angeles (UCLA) 2011
Academic Mentor, Trinity College Dublin 2016
Management Committee member, Science Foundation Ireland-funded national virtual cancer research centre Molecular Therapeutics for Cancer Ireland 2009
Founding Director, European Consortium TRAIN-EV (extracellular vesicles: for benefit in health and disease). 2017
Examiner (Report and Site Visit) for Enterprise Ireland Applied Research Capability award to Dundalk Institute of Technology 2013
Editorial Board Member, Journal of Biomarkers 2012
Founding Committee Member, Irish Association of Pharmacologists (IAP) 2016
Member of the European Federation of Pharmaceutical Scientists 2016
Management Committee member, H2020-funded cooperation in science and technology: Delivery of Antisense RNA Therapeutics 2017
Guest-Editor of book volume of Current Cancer Drug Targets entitled "Mechanisms of Cancer Drug Sensitivity & Resistance: A Translational Approach" 2009
Editorial Board Member, J. Extracell. Ves. 2013
Cancer Theme Steering Committee member, Trinity College Dublin 2012
External Examiner to Aarhus University postgraduate degree programmes 2010
Chair, International Society for Extracellular Vesicles (ISEV) Annual Conference 2022 2021-2022
Management Committee member, Irish Cancer Society (ICS)-funded national virtual cancer research centre Breast-Predict 2013
Guest-Edition of Methods in Molecular Biology: Gene Expression Profiling - 2nd Edition 2018
Editorial Board Member for Encyclopaedia of Bioscience Frontier in Bioscience 2007
Strategic Advisory Board (SAB) Member, Midatech Ltd, Oxford 2014
Frequently review for journals incl. Oncogene, Eur. J. Cancer, J. Medical Virol., Tissue Eng., J. Histochem. Cytochem., Stem Cells, Anticancer Res., Exp. Opin. Drug Discovery, BMC Development Biology, Diabetes, Obesity & Metabolism, Cancer Detect. Prevent., The Review of Diabetes Studies, Cancer Genomics & Proteomics, Differentiation, FEBS Lett., Exp. Opin. Mol. Diag., Eur. J. Pharmaceutical Sci, Experimental Haematol., Personalized Medicine, Circulation Res., Biochemica Medica, Cancer, Eur. J. Pharmacol., Leukaemia Res., Biochem. Pharmacol., Exp. Opin. Therap. Targets, J. Pharmacy & Pharmacol., Brit. J. Dermatol., Clin. Chem., BBA Cancer, Cancer Res., Nature, Nature Medicine, The Lancet 2001
Editorial Board Member, Anticancer Research 2009
Scientific Advisory Board (SAB) Member of ProEvLifeCycle, The Netherlands 2019
Molecular and Precision Oncology Theme Leader, Trinity St. James's Cancer Institute (TSJCI) 2019
Editorial Board Member, Molecular Biotechnology 2010
Management Committee member, H2020-funded cooperation in science and technology: Identifying Biomarkers through Translational Research for Prevention and Stratifictaion of Cancer 2018
Guest-Edition of Methods in Molecular Biology: Gene Expression Profiling 2009